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ABSTRACT 
 
Liquid chromatography–mass spectrometry (LC–MS) with electrospray ionisation (ESI), 
atmospheric pressure matrix assisted laser desorption ionisation/mass spectrometry (AP-
MALDI/MS) and atmospheric pressure desorption ionisation on silicon/mass spectrometry 
(AP-DIOS/MS) in positive ion mode were applied for analysis of seized drug units. Use was 
made of fast chromatographic separations on monolithic column, chiral chromatographic 
separations with two different chiral stationary phases (CSP), tandem mass spectrometry 
(MS/MS) and spectral comparison with in-house libraries.  
 
A fast LC–MS/MS method relying on monolithic column, gradient elution and an ion trap 
mass spectrometer was developed for quick identification and quantitation of 14 forensically 
interesting but chemically different compounds. Not only basic but also neutral and acidic 
compounds were efficiently ionised with ESI in the positive ion mode. All mass spectra 
showed an abundant protonated molecule, which was chosen as the precursor ion. The 
combination of retention time and MS/MS spectral information with automated library search 
enabled highly reliable identification of compounds. Results for 476 standard samples and 50 
authentic samples showed that the compounds of interest could be unambiguously identified 
with the library searching. One characteristic and abundant product ion was chosen for 
quantitative analysis. All compounds were eluted within 2.5 min and the total analysis time 
was 5 min including the stabilisation time required for the next injection. The relative 
standard deviations (RSD) were typically below ±20%, which can be considered acceptable 
for forensic semiquantitative analysis of drug seizures. The evaluation process showed good 
linearity (r > 0.993) of the method. Limits of detection (LODs) ranged from 10.0 ng/ml to 
50.0 ng/ml. 
 
In another approach, a fast LC–MS/MS method with automated library search was developed 
and validated for distinguishing the controlled drug compound 3,4-
methylenedioxymethamphetamine (3,4-MDMA, “ecstasy”) from 17 of its isomeric and 
closely related isobaric substances. 3,4-MDMA is a controlled substance whereas in many 
countries the other mass equivalent compounds are not. With single MS the compounds 
produced an intense protonated molecule, m/z = 194, and some characteristic fragments, but 
tandem mass spectrometry (MS/MS) was applied to enhance specificity. The MS/MS 
fragmentation was studied in order to distinguish 3,4-MDMA from the other 17 compounds. 
However, the MS/MS spectra of 3,4-MDMA and six other compounds were closely similar 
and the six compounds interfered in the identification of 3,4-MDMA. A fast LC–MS/MS 
method was accordingly developed for the unambiguous identification of 3,4-MDMA. The 
use of monolithic column and an MS/MS spectral library with retention times allowed 
automated confirmation of the presence of the controlled compound within five minutes. This 
qualitative method was tested with 49 ecstasy samples seized by the police. All results were 
congruent with results obtained by other methods. 
 
A preliminary study was conducted on the feasibility of AP-MALDI/MS and AP-DIOS/MS 
techniques in the identification of amphetamines and fentanyls in forensic samples. With both 
ionisation techniques, the MS spectra showed abundant protonated molecules, and the 
background did not disturb the analysis. The use of tandem mass spectrometry (MS/MS) 
allowed the identification of the amphetamines and fentanyls. AP-MALDI/MS/MS and AP-
DIOS/MS/MS were also successfully applied to identification of the compounds of interest in 
drug seizures. Common diluents and tablet material did not disturb the analysis and 
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compounds were unequivocally identified. The LOD for amphetamines and fentanyls with 
AP-DIOS/MS/MS were 100–1000 ng/ml indicating excellent sensitivity of the method. The 
LODs with AP-MALDI/MS/MS were about 5 to 10 times higher.  
 
Enantiomer separation of nine amphetamine derivatives, methorphan and propoxyphene was 
studied with use of macrocyclic antibiotic vancomycin and native β-cyclodextrin (β-CD) as 
chiral stationary phases. Effects of 46 eluent compositions on enantiomer separation in 
reversed-phase (RP) and polar ionic modes (PIM) were investigated. β-CD was found to be 
more suitable for amphetamine derivatives in general and vancomycin for methorphan and 
propoxyphene. An eluent system capable of separating the enantiomers of all amphetamines 
in one run was developed. In addition methods are reported for separation of enantiomers of 
methorphan and propoxyphene. Suitability of the eluent systems for electrospray ionisation is 
discussed, and methods employing tandem mass spectrometric (MS/MS) detection were 
developed. Suitability of chiral LC–ESI/MS/MS was tested with seized drug samples. 
Repeatability of the methods was good and LODs with mass spectrometric detection were 
25–100 ng/ml for most compounds.  
 
The methods developed and tested with seized sample material confirm that fast LC–
ESI/MS/MS, AP-MALDI/MS/MS and AP-DIOS/MS/MS and direct chiral LC–ESI/MS/MS 
can provide valuable and novel tools for analysing drug seizures. 
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1. INTRODUCTION 
 
Forensic science produces scientific and technical evidence for purposes of justice. The tasks 
of the forensic drug laboratory can be briefly summarised as detection and identification, 
interpretation, and reporting of the results. Samples investigated in a forensic drug laboratory 
commonly contain illicit drugs, prescription drugs of licit origin, and illegal cocktails of licit 
and/or illicit drugs seized by local authorities. Matrices of the samples are various: tablets, 
capsules and powders, herbal or oily material and blotter paper into which the drug is 
impregnated. Concentrations of the drugs range from relatively low to nearly one hundred per 
cent. From the analytical point of view, however, concentrations of the drugs in seized 
samples are usually high and sensitivity of the method is seldom an issue. Occasionally trace 
analyses are needed for example of the various materials used for smoking, inhaling, 
injecting, storing or wrapping the drugs. 
 
The market for street drugs, that is drugs and poisons of abuse, is continually expanding and a 
wide variety of illicit drugs have established themselves in the past 40 years. New drugs not 
controlled under legal statutes continue to appear. Explanations offered for this are increased 
availability of the scientific literature (through the internet), the availability of precursors, and 
the growing expertise of clandestine chemists. The range of relevant substances to be 
analysed expands in pace, and the physical and chemical properties of the drugs, such as 
volatility, polarity and stability, vary widely. Side by side with this, analytical methods for 
detecting and identifying known compounds and for characterising the structures of new 
molecules are in rapid development both for law enforcement purposes and for protection of 
public health (toxicology). 
 
The main aim in forensic drug analysis is the detection and unequivocal identification of 
possible illicit components in a seized drug unit. Analytical techniques that are of value in 
forensics must offer high selectivity, sensitivity, and tolerance of contaminants, and they 
should be suitable for their purpose. The routine analytical separation techniques in use today 
are gas chromatography (GC), thin-layer chromatography (TLC), liquid chromatography (LC) 
and capillary electrophoresis (CE). The introduction of mass spectrometric techniques has 
revolutionised the work of forensic laboratories, allowing them to quickly identify unknowns 
in a variety of sample materials. The mass spectrometer combines good sensitivity with high 
selectivity. The single most important technique for the identification of active substances in 
forensic drug analyses is gas chromatography–electron ionisation mass spectrometry (GC–
EI/MS). However, GC–MS only allows detection, as such, of drugs that are thermally stable, 
volatile, non-ionic and within the reach of the mass range of the instrument. LC separation, in 
contrast, can be considered more or less universal in applicability and particularly when LC is 
used in combination with electrospray ionisation (ESI) interface, even thermolabile, non-
volatile and ionic molecules become available to mass spectrometric analysis. LC–MS is 
simple, rapid, highly specific and sensitive, and in scan mode it produces unequivocal MS 
data. Furthermore, since methods offering improved sensitivity, selectivity, speed and cost are 
required for all drugs of abuse, and since MS can supply all these needs, new MS techniques 
are of great interest for forensic drug analysis.  
 
This thesis addresses the potential of atmospheric pressure ionisation mass spectrometry to 
solve the analytical problems associated with seized drugs. Three atmospheric pressure 
ionisation techniques were studied: electrospray ionisation (ESI), matrix assisted laser 
desorption ionisation (MALDI) and desorption ionisation on silicon (DIOS). In all these 
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techniques, the analytes are ionised at normal pressure outside the mass analyser. The 
advantages of this are simple introduction of the sample and direct on-line coupling of the 
sample or the analytical separation technique to the MS. The soft nature of some atmospheric 
pressure ionisation techniques and particularly ESI often results in only a protonated or 
deprotonated molecule; moreover the selectivity of single MS is not very high. Tandem mass 
spectrometry (MS/MS) with an ion trap mass spectrometer was therefore applied, and the 
fragmentation of the molecules under investigation under these conditions is briefly 
discussed. With all methods in-house mass spectral libraries were exploited for identification. 
 
The study comprised several parts. (I) Since a seized drug unit may contain numerous 
components – the principal drug of action as well as various adulterants and diluents of 
differing chemical character – a fast separation, detection and identification method was 
developed for compounds with different physical and chemical properties. As well the 
suitability of the method for quantitation of the compounds was investigated. (II) The 
growing expertise among clandestine chemists is resulting in the appearance of new 
molecules in street markets, molecules with structures only slightly modified from those of 
known illicit drugs. Standard analytical data are required for these previously unknown drugs 
of abuse and new homologue or analogue drugs. As a contribution to this direction, an LC–
ESI/MS/MS study was carried out, aimed at identification of the controlled substance 3,4-
methylenedioxymethamphetamine (3,4-MDMA, “ecstasy”) and its differentiation from a 
group of its mass equivalent and structurally similar substances. (III) As new, fast and cost 
effective techniques are continually in demand in analytical laboratories, a preliminary study 
was carried out on the potential of atmospheric pressure desorption ionisation techniques for 
the identification of illicit drugs. The new atmospheric pressure techniques: MALDI and 
DIOS with MS/MS were investigated, with amphetamine derivatives and fentanyls used as 
model compounds. (IV) The determination of chirality is sometimes important in determining 
the licit or illicit nature of a sample and useful in profiling drug batches. This is especially 
true for amphetamine-related compounds. A study was made of the effect of eluent on the 
chiral separation of different amphetamines, methorphan and propoxyphene by direct chiral 
LC with two different chiral stationary phases (CSP), and chiral LC–ESI/MS/MS methods 
were developed. The results of the four studies confirm the potential of LC–ESI/MS/MS, AP-
MALDI/MS/MS and AP-DIOS/MS/MS techniques for identification as well as quantitation 
of illicit substances in drug seizures. 
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2. REVIEW OF THE LITERATURE  
 
In the following review of the literature the compounds of interest to a forensic drug 
laboratory and the analytical techniques employed are briefly discussed. In all cases, analyses 
of drug seizure samples include screening and identification of the possible drug 
compound(s). Quantitation and chiral analyses are sometimes of interest. The chiral analyses 
of amphetamine derivatives are discussed in some detail, since their chiral separation was 
studied in this research. Development of LC–ESI/MS/MS, AP-MALDI/MS/MS and AP-
DIOS/MS/MS methods for forensic analysis was the main part of the work. The ionisation 
techniques are introduced and the previous applications of them to forensic and related 
analyses are discussed. 
 
2.1. Drugs and poisons 
 
The samples arriving in forensic laboratories contain illicit drugs, or pharmaceuticals or 
industrial chemicals that are subject to abuse or encountered in illicit markets. Mostly, the 
compounds of interest are controlled substances listed in the United Nations (UN) three 
Conventions of 1961, 1971 and 1988 [1]. The EU classifies illicit drugs according to these 
three UN Conventions. Other compounds of interest are chemical analogues of the controlled 
substances and compounds used for doping purposes. Commonly, the substances are 
classified as morphine and related narcotics, cannabinoids, cocaine, amphetamines, 
benzodiazepines, barbiturates, lysergic acid diethylamide (LSD), γ-hydroxybutyrate (GHB) 
and miscellaneous substances [2,3]. The miscellaneous substances include hallucinogens and 
anabolic steroids, growth hormone and other substances used for doping purposes. Each 
group contains frequently encountered compounds of similar chemical character or 
compounds commonly found in the same sample (e.g. cannabinoids). Classifications differ, of 
course, and are updated from time to time as the prevalence of substances changes and new 
substances appear.  
 
The compounds studied in this work included from among the controlled substances 
morphine and related narcotics, amphetamines, benzodiazepines, barbiturates and LSD and 
various anabolic steroids, psilocybin, and several other misused drugs from the miscellaneous 
group. In addition, since drug analogues are of great importance, a series of these molecules 
were included. Although most drugs of abuse are basic, there are also a few acidic and some 
neutral compounds. All these types were represented in this study. Larger molecules (MW > 
600) such as used for doping purposes were excluded. The compounds were chosen to 
broadly represent the analytical challenges in forensic drug analysis today and so represent 
stable and labile compounds, polar and nonpolar compounds, compounds found in only very 
low concentrations in seized samples, and isomeric and isobaric compounds. 
 
2.2. Forensic analyses of seized drugs 
2.2.1. Screening and identification 
 
The primary aim in forensic drug analyses is the unequivocal identification of illicit 
components in a seized drug unit. Typically various screening analyses or presumptive tests 
such as colour tests are carried out first. After the preliminary screening come the 
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confirmatory analyses, which are preferably based on different physico-chemical principles, 
are at least as sensitive as the screening analysis and provide the highest level of confidence in 
the result [4]. This two-step procedure is also employed in toxicology [5] and by international 
organisations like the World Anti-Doping Agency (WADA) [6].  
 
For laboratories involved in the forensic analysis of seized drugs there are several 
international organisations and committees charged with encouraging national laboratories to 
comply with best practice and international standards for quality and competence assurance. 
In Europe the pertinent body is the Drug Working Group (DWG) of the European Nation 
Forensic Science Institute (ENFSI) [7]. Internationally, the Scientific Working Group for the 
Analysis of Seized Drugs (SWGDRUG) Core Committee has made various recommendations 
for forensic laboratories analysing seized drugs [8]. Consisting of more than 20 forensic 
scientists from around the world, the Core Committee recommends minimum standards for 
the forensic examination of seized drugs. The recommendations encompass three main areas: 
education and training, quality assurance and methods of analysis. Minimum standards for the 
forensic examination of commonly seized drugs are presented, and analytical techniques for 
the identification of drugs are categorised. The categorisation of the techniques and the 
recommendations for their use are presented in Table 1. While this cannot be considered the 
only procedure for accomplishing reliable analyses, agreed methodologies and common 
criteria for identification of the compounds of interest, as well as inter-laboratory comparisons 
and proficiency tests, certainly improve the credibility of laboratories performing analyses. 
 
The spectroscopic techniques in group A (Table 1) provide the best resolving power for 
unequivocal identification of molecular structure. As analytical techniques they can be used 
alone or, more commonly, in combination with a separation technique from group B. The 
combination of LC with nuclear magnetic resonance spectroscopy (NMR) perhaps provides 
most information on the molecular structure [9,10], but the technique is not particularly 
sensitive. NMR is also expensive and beyond the reach of most analytical laboratories.  
 
Category B includes analytical separation techniques (electrophoretic and chromatographic 
techniques). LC and thin-layer chromatography (TLC) can be considered suitable for most 
analytes of forensic interest. TLC is often very simple and cost effective and can also be 
automated, but it suffers from poor separation efficiency and is of limited use in quantitation. 
Capillary electrophoretic (CE) techniques have high separation efficiency and selectivity and 
are particularly suitable for analysing ionic and inorganic species [11]. CE techniques suffer, 
however, from low sensitivity and poor reproducibility of the migration times. GC is often the 
most sensitive technique, but it is not suitable for polar, non-volatile, thermally unstable and 
ionic compounds, or at least not without time-consuming sample preparation. In some cases, 
the chromatographic and electrophoretic techniques lack the specificity required for 
characterising isomeric compounds or identifying new molecules and they then need to be 
used in combination with spectroscopic or spectrometric techniques.  
 
The techniques in category C are mainly used in screening and for determining whether a 
compound belongs to some specific group of drugs. Ultraviolet (UV) and fluorescence (FL) 
spectroscopy are also commonly used as means of detection in combination with LC or other 
separation technique. 
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Table 1. Categories and examples of analytical techniques according to SWGDRUG 
recommendations for the analysis of seized drugs, and the guidelines for their use. The 
selectivity of the technique diminishes from A to C. (Reproduced from the SWGDRUG report 
[8] with minor modifications.) 
Category A Category B Category C 
Infrared spectrophotometry Capillary electrophoresis Colour tests 
Mass spectrometry Gas chromatography Fluorescence Spectroscopy 
Nuclear magnetic resonance 
spectroscopy 
Ion mobility spectrometry Immunoassay 
Raman spectroscopy Liquid chromatography Melting point 
 Microcrystalline tests Ultraviolet spectroscopy 
 Pharmaceutical identifiers  
 Thin layer chromatography  
 Cannabis only: 
Macroscopic examination 
Microscopic examination 
 
1. When a validated category A technique is incorporated into an analytical scheme, then at least 
one other technique (from category A, B or C) must be used. 
1.1. This combination must identify the specific drug present and must preclude a false positive 
identification. 
1.2. When sampling size allows, the second technique should be applied on a separate sampling, 
for quality assurance reasons. When sample size is limited, additional measures should be 
taken to assure that the results correspond to the correct sample. 
1.3. All category A techniques must have data that are reviewable. 
2. When a category A technique is not used, then at least three different validated methods must be 
employed. 
2.1. These in combination must demonstrate the identity of the specific drug present and must 
preclude a false positive identification. 
2.2. Two of the three methods must be based on uncorrelated techniques from category B. 
2.3. A minimum of two separate samplings should be used in these three tests. When sample size 
is limited, additional measures should be taken to assure that the results correspond to the 
correct sample. 
2.4. All category B techniques must have data that are reviewable. 
3. For the use of any method to be considered of value, the test must be considered “positive”. 
While “negative” tests provide useful information for ruling out the presence of a particular drug 
or drug class, these results have no value toward establishing the forensic identification of a drug. 
4. In cases where hyphenated techniques are used (e.g. gas chromatography–mass spectrometry, 
liquid chromatography–diode array ultraviolet spectrophotometry), they will be considered as 
separate techniques provided that the results from each are used. 
5. Cannabis exhibits tend to have characteristics that are visually recognisable. Thus, macroscopic 
and microscopic examinations of cannabis will each be considered as Category B techniques 
when observations include documented details of botanical features. Additional testing must 
follow the scheme outlined in sections 1 and 2. 
5.1. For exhibits of cannabis that lack sufficient observable macroscopic and microscopic 
botanical detail (e.g. extracts or residues), ∆9-tetrahydrocannabinol (THC) or the other 
cannabinoids must be identified utilising the principles set forth in sections 1 and 2. 
6. Examples of reviewable data are: 
6.1. printed spectra, chromatograms and photographs or photocopies of TLC plates 
6.2. contemporaneous documented peer review of the tests for microcrystalline tests 
6.3. recording of detailed descriptions of morphological characteristics for cannabis 
6.4. reference to published data for pharmaceutical identifiers 
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Gas chromatography combined with electron ionisation/mass spectrometry (GC–EI/MS) is 
considered the “golden standard”, or the reference method for confirmation of positive 
screening tests [12,13]. GC–MS is recommended as the confirmatory technique in the 
Forensic Toxicology Laboratory Guidelines [5]. In both systematic toxicological analyses and 
forensic analyses of drug seizures, GC–MS in scan mode is also commonly used in screening. 
Scan mode allows the detection and identification of many drugs or potential drugs at the 
same time [4,14].  
 
The advantage of mass spectrometry over other analytical techniques common in drug 
analysis (Table 1) is that MS as such can be considered a universal detector [15] and the 
amount of information obtained is very large. Often a single spectrum offers the means for 
identification, and even quantitation of the components can be accomplished with a minute 
amount of sample, owing to the high sensitivity and specificity of the technique. The 
identification of a compound on the basis of its mass spectrum is accomplished by comparing 
the recorded spectrum against the mass spectrum of a reference compound or spectra in a 
spectral library. An identification in confirmation analyses can also be based on just a few 
selected structure-specific ions. Suggestions have been made, and also official guidelines 
drawn up, for the criteria for the identification of compounds with use of different MS 
techniques [5,6,16,17]. 
 
As a means to widening the application range of mass spectrometry, and since no single 
chromatographic technique is capable of separating all possible components LC–MS has 
found an increased number of forensic applications during the past few years. Interest in LC–
MS increased markedly after the introduction of commercial ESI and atmospheric pressure 
chemical ionisation (APCI) interfaces. Already several broad-scale drug screening 
applications have been developed [18–29].  In these atmospheric pressure ionisation (API) 
interfaces the ionisation of the analytes takes place at normal pressure outside the mass 
analyser. The ionisation at normal pressure makes the introduction of a sample and direct on-
line coupling of the analytical separation techniques to the MS simple, and the analyses are 
more stable. LC separation is considered an almost universal technique, and LC–MS allows 
the analysis of thermally labile, non-volatile, polar and ionic compounds which cannot be 
directly analysed by GC–MS. 
 
2.2.2. Quantitation 
 
Because a fast qualitative response is often all that is needed for the immediate decision-
making of the police or court, the main emphasis in the analysis of seized drugs is on 
qualitative analysis. In some instances, however, determination of the purity of the drug 
seizure is of importance. The court’s primary interest then is to make the legal distinction 
between possession and trafficking of substances, or to grade offences of possession as minor 
or serious. Sometimes mere weighing of the sample can be considered a quantitative analysis, 
but no country within the EU definitively uses quantity to decide who is a user and who a 
trafficker [30].  
 
The methods used in chemical quantitation of the active substance of a sample are mostly the 
same as used in qualitative confirmation methods after the primary screening: that is, LC, GC 
and nowadays also capillary electrophoretic techniques (CE) [11,31]. Quantitation is 
commonly performed after the identification and the methods are targeted to and optimised 
for specific analyte(s) and matrices.  
 14 
2.2.3. Chiral analyses 
 
Chiral analyses can be important for compounds appearing in different enantiomeric forms. 
Amphetamine derivatives, especially 3,4-methylenedioxymethamphetamine (3,4-MDMA) 
and methamphetamine (MA), are chiral compounds and among the most important drugs 
produced in clandestine laboratories [32]. The methods of synthesis may be achiral or chiral, 
which means that chiral analysis of a seizure can provide valuable information for 
investigative purposes [33]. This “profiling”, as it is called, is one of the most intriguing areas 
in forensic analysis today, because of the possibility to establish links between clandestine 
laboratories and drug distributors. At present the most common method for profiling does not, 
however, involve chirality determinations but rather determinations of chemical impurities 
and profiling of by-products in a specific drug batch [34].  
 
In the case of some drugs, the optical isomers possess different pharmacological and 
pharmacokinetic properties and therefore different toxicological properties [35], which makes 
the chiral information important as a national health issue. For example, the S-(+)-
enantiomers of amphetamine (AM) and MA possess higher psychostimulant activity than do 
the R-(-)-enantiomers. For law enforcement purposes the most critical reason for doing chiral 
analyses in a forensic laboratory is where only one optical isomer is controlled under legal 
statutes. EU legislation, for example, criminalises only one isomer of propoxyphene and 
methorphan, while in the United States the possession of crystal S-(+)-MA (known as “ice”) 
will usually lead to more severe penalties [36].  
 
A collection of methods that have proved useful in analysing the enantiomers of amphetamine 
derivatives in drug seizures, over-the-counter or other medicaments, herbal products and 
biological material are listed in Table 2. Emphasis is on the chiral analysis of drug seizures 
and on chiral screening analysis of several amphetamines. Chiral separations can be 
performed with the use of chiral stationary phases (CSPs) or with achiral columns and 
diastereomer formation through derivatisation with a chiral reagent. Also, chiroptical 
detectors can be used. Today, amphetamine derivatives are mostly enantiomer separated by 
GC with derivatisation, by CE with a chiral selector in the running buffer, or by direct LC.  
 
GC technique is mainly targeted to the analysis of biological samples because of its sensitivity 
(see Table 2). The disadvantage is the time-consuming derivatisation with a possible source 
of error. The derivatising reagents can lack stereochemical purity and stability and may 
undergo unpredictable racemisation [37,38]. In addition, the evaporation steps may lead to 
loss of the volatile amphetamine derivatives.  
 
CE has become a popular technique for separation of the enantiomers of amphetamine 
derivatives, performed either indirectly by diastereomer formation or, more commonly, 
directly by addition of a chiral selector to the background electrolyte. Native or modified β-
cyclodextrin (β-CD) has proven to be the most successful chiral selector to date (Table 2). α- 
and γ-CDs have been applied without much success, though γ-CD is an efficient selector in its 
more water soluble, highly sulphated form (Table 2). The poor reproducibility of the CE 
migration times can be overcome with the use of internal standards or MS detection. While, 
the sensitivity continues to be fairly low, it can be improved through the use of derivatising 
reagents that introduce a fluorescing group to the analyte and the use of a sensitive 
fluorescence (FL) detector. Derivatisation has also been attempted with LC [39–42]. The 
main advantage of CE is its high efficiency, which means that the actual analytical runs can 
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be accomplished quickly. A good example of this is the method of Wallenborg et al.[43] in 
which on-chip CE is used with highly sulphated γ-CD (HS-γ-CD) and laser induced 
fluorescence (LIF) detection. Enantiomer separation was achieved for five amphetamine-
related compounds in four minutes and for six in seven minutes. A fluorescent tagging 
reaction with 4-fluoro-7-nitrobenzofurazane (NBD-F) was also accomplished in a few 
minutes. Belder et al.[44] were able to baseline separate the enantiomers of norephedrine 
(NE) in just 2.5 seconds by microchip CE with HS-γ-CDs and linear imaging UV detection. 
This, they believed, was record time for a chiral separation. 
 
Chiral LC has been used for amphetamine derivatives in both indirect and direct mode. 
Achiral LC with on-line circular dichroism (CD) detection is a technique that does not require 
the separation of enantiomers in order to identify them. It is less sensitive than UV, however, 
it requires a chromophore and, with complex mixtures, it frequently requires some separation 
of compounds [45]. In direct chiral LC analyses, the column is coated with a chiral stationary 
phase (CSP) and the analytes are separated without prior derivatisation. Time is saved and 
errors related to derivatisation are avoided. Direct LC separations have become more popular 
with the availability of new, more selective and more rugged CSPs, as can be seen in Table 2.  
 
In direct chiral LC analyses the most widely used CSP for separating the amphetamine 
derivatives has been native or modified β-CD (Table 2). Crown ether has been used as well, 
but it does not form a complex with a secondary amine and thus MA was not separated with it 
[46]. Protein [47–49] and specifically prepared immunoaffinity [51] columns have also been 
successfully applied. Vancomycin chiral selector had not been applied to amphetamine 
derivatives before the present work, probably because it had been found more suitable for the 
separation of acidic compounds [51]. Vancomycin has many of the separation characteristics 
of protein based stationary phases, including exceptional stability and higher sample capacity 
[52]. Vancomycin is a glycopeptide that belongs to macrocyclic antibiotic phases. Structures 
of the macrocyclic antibiotics are highly complex; for example the vancomycin molecule 
produced by Streptomyces orientalis contains 18 chiral centres with various functional groups 
surrounding its three pockets or cavities [53]. Possible interactions with the analyte include π–
π complexation, hydrogen-bonding, inclusion complexation, dipole interactions, steric 
interactions, and anionic and cationic binding. The strengths of these interactions depend on 
the type of mobile phase employed [53]. Vancomycin has been used with different techniques 
and for many different analytes since its introduction [54]. It has been used not only in LC, 
but in CE, in thin-layer chromatography (TLC)[55], enhanced fluidity liquid chromatography 
(EFLC)[56], supercritical fluid chromatography (SFC)[57] and capillary 
electrochromatography (CEC)[58]. With mass spectrometric detection, it has been used at 
least with CE–ESI/MS [59] and with LC–APCI/MS [60,61]. Earlier studies have 
demonstrated the utility of the vancomycin column in LC analyses of also basic compounds 
(e.g. ergot alkaloids [62]). 
 
The chiral separation methods for enantiomers of AM and MA developed by Katagi et al. in 
1994 with thermospray ionisation (TSP) [63] and later with ESI [64] interfaces were among 
the very first LC–MS applications for these analytes. Still, chiral LC in combination with 
mass spectrometry has rarely been used, even though it can provide the sensitivity and 
specificity often needed and MS offers a more universal detector than FL. In the case of 
amphetamine derivatives, for example, FL detection is not always effective for those that are 
non-fluorescing. As is presented in Table 2 the LC methods with FL detection provide similar 
limits of detection (LODs) to LC–MS methods, but the more common UV detection is clearly 
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less sensitive. It should be noticed that most of the LC methods listed in Table 2 are not 
directly suitable for ESI and APCI mass spectrometry because of the use of nonvolatile 
phosphate buffer. Some modifications are necessary.  
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Table 2. Selection of GC, CE and LC methods for the chiral separation of amphetamine derivatives and related compounds. 
Compoundsa Matrix Derivatisationb Separation, commentsc Detection and 
Details 
LOD (ng/ml) Linearity  
(ng/ml) 
Ref. 
EP, PS,MA, MC Stds MTPA GC: DB-5 (15 m x 0.25 mm x 0.25 µm), 190°C (1 min)–2°C/min–
220°C (1 min)-20°C/min–275°C, inj. V 1 µl, split 1/25, runtime 14 
min 
FID, MS 
(1H-
NMR; 
offline) 
n.d. n.d. n.d. [65] 
MDMA, MDA, 
metabolites 
Stds, 
synthesis 
products, 
urine 
(S)-HFBPCl+ 
MSTFA+MBTF
A -> N-(S)-
HFBP--O-TMS 
GC: DB-5MS (15 m x 0.25 mm x 0.25 µm), 105°C(7.5min)–
10°C/min–200°C (10min)–20°C/min–280°C 
MS (SIM) 
QIT 
EI, 
PCI (i-
Bu) 
n.d. n.d. [38] 
MDMA, MDA, 
AM, metabolites 
Urine 
plasma 
(R)-MTPCl 
and 
(S)-MTPCl 
GC: DB17 (30 m x 0.25 mm x 0.25 µm) (urine) HP Ultra 1 (25 m 
x 0.2 mm x 0.11 µm) (plasma), 100 °C (3 min)–15 °C/min–285 
°C(5 min) 
NPD (U), 
MS (Pl) 
SIM, 
MRM 
LOQ 0.1 (U) 
and 0.05 (Pl) 
for MDMA 
(MS) 
0.1–80 
(pl) 
0.025–8 
(u) for 
MDMA  
[37] 
AM, MA, MDA, 
MDMA, MDEA 
Urine l-TPC GC: DB-17 or ZB-50 (15 m x 0.25 mm x 0.25 µm), 120°C-
30°C/min-210°C-6°C/min-260°C (1 min), splitless, and HP-1 (12 
m x 0.2 mm x 0.33 µm), 130°C-4°C/min-190°C-25°C/min-250°C 
(2 min), splitless. Runtimes 15 and 20 min, respectively 
MS  SIM LOQ 10 (AM, 
MA), 25 (MDA, 
MDMA, MDEA)
5–10000  [66] 
MDA, MDMA, 
HMA,HMMA 
Stds, 
urine 
1) (R)-MTPCl 
+NH4OH 
2) HMDS 
GC: Ultra 2 AT (12 m x 0.22 mm x 0.33 µm), 150°C(1 min)-
20°C/min-290°C (7 min), split 1/10, inj. V 2 µl 
MS SIM (3 
ions, 1 
quant.) 
2.4/3.1 (R/S-
MDMA), 
0.2/0.3 (R/S-
MDA) 
12.5–200 
(MDMA) 
1.25–20 
(MDA) 
[67] 
AM, MA, NE, 
NP, EP, PS 
Stds, 
forensic 
samples 
GITC MECC: DM-β-CD + 200 mM SDS, 20% MeOH, T=30°C, 15 kV, 
runtime 25 min 
 
UV 210 nm n.d. n.d. [68] 
DM-4-MA, EP, 
PS, NE, AM, 
MA, BDMA, 
MDA, MDMA, 
MDEA 
Stds No CE: 120 mM HP-β-CD, 100 mM citric acid-19.27 mM Na2HPO4, 
pH 2.5, NE, DM-4-MA, BDMA no chiral Rs, runtime for all 50 
min 
 
UV 200 nm n.d. n.d. [69] 
AM, NE, NP, CA, 
MrCA, cocaine, 
MA, EP, MC, 
MrCAT, 
Propoxyphene 
Stds, 
forensic 
samples 
No CE: Mixture of anionic and neutral CDs e.g. DM-β-CD and β-CD-
SBE(IV), MeOH/25 mM Tris-H3PO4 buffer, pH 2.45 e.g. 1.2:98.8, 
30 kV, T=30°C runtimes 14 to 28 min 
 
UV 210 nm n.d. n.d. [36] 
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Table 2. (Continued) 
Compoundsa Matrix Derivatisationb Separation, commentsc Detection and 
Details 
LOD (ng/ml) Linearity  
(ng/ml) 
Ref. 
EP, PS, N-MEP, 
N-MPS, NE, NP, 
AM, MA 
Stds, 
herbal 
prep. 
No CE: 70 mM HP-β-CD – 30 mM TMAC –10 mM SDS, pH 2.0, 28 
kV, T=31°C, NE no chiral Rs, runtime 41 min 
UV 210 nm 4000 4000–
100000 
[70] 
MA, AM, 4-HA, 
4-MA, MDMA, 
MDEA, DMA, 
DMMA, BDMA 
Stds No (yes; Marfey’s 
reagent tested but it 
brought no extra 
advantage) 
CE: 10 mM native β-CD, DM-β-CD, TM-β-CD, HP-β-CD and/or 
CM-β-CD, 50 mM NaH2PO4, 20 kV, 20°C, at least partial 
separation for all with native β-CD, analysis times different, all < 
32 min, most < 12 min 
UV 214 nm n.d. n.d. [71] 
AM, MA, MDA, 
MDMA, MDEA 
Stds, 
urine 
No CE: 20 mM HP-β-CD (α- and other β-CDs also tested), 200 mM 
NaH2PO4 25 kV, 15°C runtime for mixture 30 min 
UV 
(DAD) 
200 nm n.d. 500–
10000 
[72] 
AM, MA, 
selegiline 
Stds Yes and no GC: DM-β-CD (Chiraldex) (with and without derivatisation) 
LC: HP-β-CD, S-NEC-β-CD, DMP-β-CD with AQC deriv. 
CE: HP-β-CD 
FID, UV 254 nm 
214 nm 
(MA) 
n.d. n.d. [42] 
MDA, MDMA, 
MDEA 
Stds, 
synthesis 
products 
No CE: α-, β-, γ-CD tested; β-CD the only that provided separation in 
3 diff. buffer systems, runtime 20 min 
ESI+,MS 
(SIM) 
[M+H]+s 3000 n.d. [73] 
AM, MA, PE Stds No CE: α-, β-, γ-CD and DM-β-CD tested  12 mM DM-β-CD, 50 
mM Tris-H3PO4, pH 2.3, 22 kV, ambient T, runtime 10 min 
UV 210 nm n.d. n.d. [74] 
AM, MA, EP Stds, 
urine, hair 
No CE: α-, β-, γ-CD tested  15 mM β-CD, 150 mM phosphate 
buffer, pH 2.5, 10 kV, T=17.5°C, runtime 30 min 
UV 200 nm 300 625–
20000 
[75] 
MA, AM, EP, NE, 
DMeA, N-MEP, 
MDMA, MDA, 
MDEA 
Stds, 
urine 
No CE: β-CD, DM-β-CD, TM-β-CD, HP-β-CD examined  mixture 
only choice: 3 mM β-CD+10 mM DM-β-CD, pH 2.5, +30 kV, 
75mM Tris, T=25° C, 3 s injection, runtime 33 min 
UV 195 nm 100 200–
500000 
[76] 
NE,EP,CA,PS, 
MC,AM,MA 
Stds NBD-F Microchip CE (MCE): Best: highly sulphated γ-CD (10mM)+1.4 
mM SDS buffer phosphate 50 mM, pH 7.35, 8 kV, runtime 7 min 
LIF 488nm 
Ar laser 
n.d. n.d. [43] 
EP, NE, NP, PS Stds, 
herbal 
material 
No CE: 10 mM l-leucine as chiral selector, 20 mM phosphate buffer, 
pH 9.0, 20% i-PrOH, 15 kV, T=25°C, compounds separated from 
one another in 7 min 
UV 190 nm n.d. 3330–
20000 
[77] 
NE, NP, EP, PS, 
AM, MA, MDA, 
MDMA,MDEA 
Stds No CE: HS-γ-CD, (SU(XIII)-γ-CD). Optimised to high CD conc. 
(10mM), 50 mM phosphate background electrolyte at pH 2.6, -12 
kV, cap. T=15°C. 
UV 195 nm 0.012 (NE) n.d. [78] 
EP, PS, MA, 
phentermine 
(ISTD) 
Stds, 
forensic 
samples 
No CE: 15 mM β-CD, 300 mM NaH2PO4, pH 2.5, 20 kV, 30°C 
runtime 30 min 
UV 200 nm 3000 5000–
25000 
[79] 
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Table 2. (Continued) 
Compoundsa Matrix Derivatisationb Separation, commentsc Detection and 
Details 
LOD (ng/ml) Linearity  
(ng/ml) 
Ref. 
MA, MC, PS, EP 
(ketamine) 
Stds, 
forensic 
samples, 
urine 
No CE: 17.5 mM native β-CD, H2O/ACN 95:5+150 mM phosphate, 
pH 2.5, 20 kV, T=15 °C, runtime <20 min 
GC: HP-5 MS (30 m x 0.32 µm) 70°C (1min)–15°C/min–200°C 
(2 min)–20°C/min–260°C (12.3 min), splitless, runtime 27 min 
UV 
MS 
(GC) 
210 nm 
full scan 
40–450 
m/z 
1.0 (GC) n.d. [80] 
NE, NP, EP, PS, 
AM, MA, MDA, 
MDMA, MDEA 
Stds, 
synthesis 
products 
No, d-
isoproterenol 
(ISTD) 
CE: 2.5 mM HS-γ-CD, (SU(XIII)-γ-CD), RP mode, cap. T=15°C. (+)ESI/ 
MS/MS 
[M+H]+s 
(QTOF) 
10 000 n.d. [81] 
MA, PS, EP Stds, 
forensic 
samples 
GITC LC: Bondapak C18 (30 x 3.9 mm), 1) THF/H2O/HOAc 35:70:1; 2) 
MeOH/H2O/HOAc 50/49/1; 3) phosphate buffer, pH 3.0/MeOH 
5/1, 1.5 ml/min, ambient T, runtime 30 min 
UV 254 nm 
280 nm 
n.d.d n.d. [82] 
MA, AM Stds l-TPC LC: Pirkle covalent phenylglycine or Pirkle ionic phenylglycine 
(25 x 4.5 cm), various amounts of i-PrOH in hexane, inj. V 20 µl 
moving 
belt-
EI/MS 
UV 
full scan 
m/z 71–
450 
254 nm 
n.d. n.d. [83] 
MA, AM Urine No LC: Phenylcarbamate-β-CD (Ultron ES-PhCD), ACN/MeOH/50 
mM KPO4 10/30/60, pH 6.0 (UV), and ACN/MeOH/100 mM 
NH4OAc 10/30/60, pH 6.0 (TS-MS), 1.0 ml/min, T=25°C 
TS–MS 
UV 
SIM 
220 nm 
0.2–0.5 (SIM) 
3–10 (scan) 
50–100 (UV) 
n.d. [63] 
AM, MA, 4-HA, 4-
MA, MDMA, 
MDEA, DMA, 
DMMA, DM-4-
EA, BDMA 
Stds, 
forensic 
samples 
No or 
PITC, NITC, 
Marfey's, 
AQC 
LC: Native β-CD (250 x 4.0 mm x 5 µm) + achiral for derivatised 
compounds, 0.1 M NH4OAc, pH 7 and 5 to 15% MeOH, 0.4/0.5 
ml/min; only partial separation for DE-4-EA, runtime 39 min 
UV non-deriv. 
254 nm 
n.d. n.d. [84] 
EP, MA, 
selegiline 
Stds No LC: Native β-CD, Chiradex (250 x 4,0 mm x 5 µm), 500 M TEA 
with H2SO4, pH 3.5, no organic, 0.8 ml/min, runtime 39 min 
UV 
(DAD) 
206 nm n.d. n.d. [85] 
AM, MA, NE Stds, 
urine 
No LC: Chiral crown ether CROWNPAK CR(+) (150 x 4.0 mm), 1.0 
ml/min, aq. HClO4, pH 1.8 
UV 
(PDA) 
200 nm 
254 nm 
1500 n.d. [46] 
MA, AM, metab. Stds,  
urine 
No LC: Phenylcarbamate-β-CD column (Ultron ES-PhCD) (150 x 6.0 
mm x 5.0 µm) ACN/MeOH-50 mM KPO4 (UV), 100 mM 
NH4OAc/MeOH/ACN (60/30/10), pH 6.0 (TS), 1 ml/min, native 
β-CD as reference column, runtime 20 min 
UV 
TS-MS 
220 nm 
SIM, 
[M+H]+s  
50 (UV), 0.5 
(MS) (AM), 100 
(UV) (MA), 1.0 
(MS) (MS) 
200–
20000 
(UV) 
[86] 
MDA, MDMA, 
MDEA, MBDB 
Stds, 
forensic 
samples, 
blood 
No LC: Native-β-CD, Astec Cyclobond I 2000 (250 x 4.6 mm x 5 
µm) or HPE-β-CD, Astec Cyclobond 2000-RSP (same dim.), 
KH2PO4/K2HPO4 0.1 M, pH 6.5, 1.0% TEA/ACN 95/5 v/v 
T=30°C, 1.0 ml/min runtime 36 min 
FL ex 285 nm
em 320 
nm 
HPE-β-CD 
11–24 
LOQ 37–80 
HPE-β-
CD 
50–3000 
 
[87] 
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Table 2. (Continued) 
Compoundsa Matrix Derivatisationb Separation, commentsc Detection and 
Details 
LOD (ng/ml) Linearity  
(ng/ml) 
Ref. 
AM, EP, PS Stds, 
tablets 
FMOC or 
FMOC-L-Pro 
LC: FMOC derivatives: native β-CD ChiraDex (250 x 4 mm x 5 
µm)  
Achiral for FMOC-l-Pro derivatives, RP (ACN/MeOH, phosphate 
or NH4OAc) and NP (hexane/PrOH, ACN/EtOAc) and PIM 
(ACN/HOAc/TEA) 
FL 
UV 
ex 264 nm
em 313 
nm 
UV 254 
nm 
FMOC-L-Pro: 10 
(AM), 25-50 
(EP, PS) (FL) 
100 (AM, EP), 
250-500 (PS) 
(UV) 
500–
20000 
[40] 
MA, AM Urine No LC: Phenylcarbamate-β-CD column (150 x 2.0 mm), 10 mM 
NH4OAc/MeOH/ACN (60/30/10), pH 5.0, 150 µl/min, 25°C, total 
runtime 30 min 
(+)ESI–
MS 
scan and 
SIM: 
[M+H]+s 
20 and 50 
(scan), 0.5 and 
1.0 (SIM) 
(MA, AM)  
1.0–5000 
 
[64] 
MDEA, MDA, 
metab., MDMA 
(ISTD) 
Plasma No LC: 1) ChiraDex (250 x 4 mm) runtime 25 min, 0.8 ml/min, 40 
mmol KH2PO4, pH 5.5/ACN 91/9, inj. V 20µl 
2) LiChroCart Superspher 60 RP-select B (250 mm x 4 mm x 5 
µm) and 0.01 M β-CD in 40 mmol KH2PO4, pH 3.0/ACN 98/2, 0.5 
ml/min, inj. V 20 µl, runtime 33 min 
3) Chiral CBH 150 mm x 4 mm (metabolites) 
FL 
(MDA, 
MDEA) 
ECD 
(HME) 
ex 286 nm
em 322 
nm 
(MDEA, 
MDA) 
LOQ 5.0 (FL) 1.2–20.3 
(MDA). 
10.1–
175.9 
(MDEA) 
[47] 
AM, NE, NOE, 
MDA 
Stds, 
urine, 
plasma 
OPA+NAC LC: Lichrospher 100 RP18 (125 x 4 mm, 5 µm), MeOH/OAc 
buffer, pH 4.5, 50/50 (60/40 for NOE), 0.75 ml/min, runtime 45 
min, 60/40 MeOH/OAc buffer, pH 4.5, 1.0 ml/min, runtime 25 
min 
FL em 231 
nm 
ex 425 nm
25 (NE, NOE) 
50 (AM, MDA)
LOQ 100 
and 250 
250–
750(?) 
[41] 
MA, AM Stds, 
urine 
No and yes with 
GC–MS 
LC: Anti-D-MA monoclonal Ab column, fraction collection (i.e. 
complicated) Syva Emit d.a.u. or derivatisation and GC–MS 
EMIT, 
GC-MS 
SIM 1100 (LC–
(offline)–GC–
MS) 
n.d. [50] 
MA Stds, 
forensic 
samples 
No LC: Chiralcel OB-H, n-hexane/i-PrOH 9/1 v/v, 1.0 ml/min, 
runtime < 15 min 
UV 220 nm n.d. n.d. [48] 
MDEA, MDA, 
metab. 
Plasma,  
urine 
No LC: Chiral CBH column (150 x 4 mm x 5 µm) with CBH guard 
column (10 x 3 mm, 5 µm), 20 mM NaH2PO4, 50 mM Na2EDTA+ 
7% i-PrOH, pH 6.44, 0.7 ml/min, 17.5°C, runtime 22 min 
FL em 286 
nm 
ex 322 nm
LOQ 5 5–100–800 
(MDEA), 
5–200 
(MDA); 
U 
[49] 
AM, yohimbine Stds, 
seized 
drugs 
No LC: C8 (250 x 4.6 mm, 3 µm), A: phosphate buffer pH 3.7, B: 
ACN, 0-10 min 10–30% B, 10- 20 min 30% B, 1.0 ml/min, 
T=25°C, inj. V 10 µl, runtime 20 min. 
CD less sensitive than UV, but chiral separation not required. 
UV/Vis 
CDe 
258 nm n.d. n.d. [45] 
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Table 2. (Continued) 
Compoundsa Matrix Derivatisationb Separation, commentsc Detection and 
Details 
LOD (ng/ml) Linearity  
(ng/ml) 
Ref. 
AM, MA, NE, 
PMA, PCA, 
PMMA, MDA, 
MDMA, MDEA  
Stds, 
seized 
drugs 
No LC: Native β-CD (150 x 4.6 mm x 5 µm), 95/5 100 mM 
NH4OAc/MeOH, 0.8 ml/min, 15°C, inj.V 20 µl, runtime 55 min, 
NE no chiral Rs. 
Vancomycin (150 x 4.6 mm x 5 µm), MeOH/HA/TEA 
100/0.03/0.02, 0.8 ml/min, 15°C, inj.V 20 µl, runtime 20 min: 
MDEA, NE no chiral Rs, other 0.5 < Rs < 1.5, peaks overlapping 
 MS required 
(+)ESI/ 
MS/MS 
MRM 
[M+H]+ 
100, 1000 
(AM) 
(β-CD) 
n.d. IV 
aAbbreviations for compounds not already mentioned: 4-HA: 4-Hydroxyamphetamine; 4-MA: 4-Methoxyamphetamine; BDMA: 4-Bromo-2,5-dimethoxyamphetamine; CA: 
Cathinone; DM-4-EA: 2,5-Dimethoxy-4-ethyl amphetamine; DM-4-MA: 2,5-Dimethoxy-4-methyl amphetamine; DMA: 2,5-Dimethoxyamphetamine; DMeA: 
Dimethylamphetamine; DMMA: Dimethoxymethamphetamine; EP: Ephedrine; MBDB: N-Methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine; MC: Methcatinone; MrCA: 
Merucathinone; MrCAT: Merucathine; N-MEP: N-Methylephedrine; N-MPS: N-Methylpseudoephedrine; NOE: Norepinephrine; NP: Norpseudoephedrine; PE: 
Phenylephrine; PS: Pseudoephedrine. 
bThe abbreviations used for the derivatisation reagents: AQC: 6-Aminoquinolyl-N-hydroxsuccinimidyl carbamate; DPIBCl: 4-(4,5-Diphenyl-1H-imidazol-2-yl)benzoyl 
chloride; FMOC-L-Pro: 9-Fluorenylmethyl chloroformate-L-proline; (R)-MTPCl: (R)-(–)-α-Methoxy-α-trifluoromethylphenylacetyl chloride; Mosher's reagent, (S)-MTPCl: 
(S)-(+)-α-Methoxy-α-trifluoromethylphenylacetyl chloride; GITC: 2,3,4,6-Tetra-O-acetyl-β-D-gkucopyranosyl isothiocyanate; HMDS: 1,1,1,3,3,3-Hexamethyldisilazane; 
Marfey's reagent: N-α-(2,4-Dinitro-5-fluorophenyl)-L-alaninamide; l-TPC: trifluoroacetyl-l-prolyl chloride; MBTFA: N-Methylbis(trifluoroacetamide); MSTFA: N-Methyl-
N-trimethylsilyltrifluoroacetamide; MTPA: (R)-(+)-α-Methoxy-α-(trifluoromethyl)phenylacetic acid; N-(S)-HFBPCl: N-Heptafluorobutyryl-(S)-prolyl chloride; NAC: N-
Acetyl-L-cysteine; NBD-F: 4-Fluoro-7-nitro-2,1,3-benzoxadiazole, 4-fluoro-7-nitrobenzofurazane; NITC: Napthyl isothiocyanate; OPA: o-Pthaldialdehyde; PFPP: 
Pentafluorophenylpropyl; PITC: Phenyl isothiocyanate; S-TFPC: (S)-(–)-N-(Trifluoroacetyl)-prolyl chloride; TMAC: Tetramethylammoniumchloride.  
c Other abbreviations in the table, if not already mentioned: U: Urine; Pl: Plasma; β-CD-SBE(IV): Anionic, randomly substituted sulfobutyl ether β-CD; DM-β-CD: 
Heptakis(2,6-di-O-methyl)-β-cyclodextrin; DMP-β-CD: Dimethylphenylcarbamate-β-cyclodextrin; EMIT: Enzyme multiplied immunoassay; HP-β-CD: Hydroxypropyl-β-
cyclodextrin; HS-γ-CD: Highly sulphated-γ-cyclodextrin; S-NEC-β-CD: S-Napthylethylcarbamate-β-cyclodextrin; SDS: Sodium dodecyl sulphate; PCI: Positive chemical 
ionisation; SIM: Selected ion monitoring. 
dn.d. = not determined/reported, 
eCD = circular dichroism. 
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2.3. Atmospheric pressure ionisation/mass spectrometry in forensic drug analyses 
 
Many of the compounds that are of interest for forensic analysis cannot be directly analysed 
by GC–MS, the “golden standard” technique for confirmation of compound identity. Some 
compounds break into smaller compounds in the heat of the GC injector, an obvious problem 
for unequivocal identification. For this, and other reasons already discussed, the combination 
of LC and MS and especially the introduction of the API interfaces have been important for 
forensic drug analyses. The following sections briefly describe the three API techniques that 
were used in this study and describe some existing applications for analysing the analytes of 
interest. 
 
2.3.1. Ionisation techniques used in the study 
 
The atmospheric pressure ionisation techniques used in this study were electrospray ionisation 
(ESI), matrix assisted laser desorption ionisation (MALDI) and laser desorption ionisation on 
silicon (DIOS). In MALDI, α-cyano-4-hydroxy cinnamic acid (α-CHCA) was used as matrix, 
while DIOS was performed using a porous silicon platform without any matrix. The 
desorption ionisation techniques are not integrated with LC in a dynamic way. Some attempts 
to accomplish automated coupling have been reported, however [88,89]. Other atmospheric 
pressure ionisation techniques available and used in analysing for illicit drug compounds 
include atmospheric pressure chemical ionisation (APCI) [90] and markedly less frequently 
sonic spray ionisation (SSI) [91] and atmospheric pressure photoionisation (APPI)[92].  
 
Electrospray ionisation was chosen for the method development owing to its capability to 
efficiently produce ions from a variety of compounds and for its soft nature; it mostly 
produces a protonated molecule without fragment ions. ESI [93–95] involves the nebulisation 
of a liquid stream into charged droplets through the action of the high electric field applied to 
the (metal) capillary. A pneumatic nebulisation gas (nitrogen) is commonly added to assist the 
droplet formation. The liquid subsequently breaks into smaller charged droplets through 
solvent evaporation with the help of heat or drying gas or both. At the Rayleigh limit, the 
small, densely charged droplets undergo Coulombic explosion. After several successive 
fissions the radii of the highly charged droplets are very small (<10–20nm) and the droplets 
are finally transformed into gas-phase ions. The generation of gas-phase ions from the 
microdroplets is a result of either desorption of the ions from the droplet surface or the 
desolvation of preformed ions, or both. These two models are called the ion-evaporation 
model (IEM) and the charged-residue model (CRM), respectively. The formed gas-phase ions 
are then directed into an orifice leading to the vacuum of the mass analyser. 
 
As a soft ionisation technique, ESI is suitable for the analysis of thermally labile, otherwise 
fragile and non-volatile polar or moderately nonpolar organic molecules [93]. Because ESI 
can produce multiply charged ions from large biomolecules, the analysis even of whole 
proteins is possible. ESI is compatible with LC separations and is especially suitable for 
compounds that can be ionised in solution. The solution chemistry is sometimes critical as 
surface tension, conductivity and volatility of the solvent, among others, play an important 
role in the ionisation process.  
 
MALDI was initially introduced for the analysis of high molecular mass compounds [96,97]. 
As a soft ionisation technique, its utility lies in an ability to provide molecular weight 
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information on intact molecules, good sensitivity and suitability to analysis of complex 
mixtures. In MALDI the analyte is mixed with a matrix and the mixture then co-crystallises 
on the target plate. A pulsed laser beam irradiates the co-crystal causing the accumulation of 
high-density energy within the crystal, which causes both the analyte and the matrix to 
vaporise. The matrix helps transfer the required energy of the pulsed laser beam to the analyte 
in order to vaporise and ionise it [96,98]. It also reduces the required desorption energy. The 
exact desorption ionisation mechanism is not known.  
 
MALDI is commonly performed in vacuum, but recently an atmospheric pressure (AP)-
MALDI ion source was developed [99]. Ionisation at atmospheric pressure makes the 
analyses easier to perform and the ionisation is even softer than in vacuum [100]. More 
importantly, the AP-MALDI source is compatible with all types of mass analysers, whereas 
vacuum-MALDI is typically used with the time-of-flight (TOF) analyser. Commercial AP-
MALDI sources are easily interchangeable with ESI sources. 
 
Even more recent than AP-MALDI is the AP-DIOS technique [101]. In this MALDI-related 
but matrix-free, soft laser desorption ionisation technique, analyte and solvent molecules are 
trapped on the high surface area of porous silicon [102–104]. From the silicon surface the 
analytes are directly desorbed and ionised through irradiation with a laser. Porous silicon has 
proven to be an effective medium for desorbing compounds and generating intact ions in the 
gas phase [102]. The lack of matrix allows the analysis of small molecules (MW < 500) with 
low background because there are no ions from the matrix to interfere the analysis. The lack 
of matrix also allows more uniform deposition of aqueous samples [98]. Sensitivity at the 
femtomole level with little or no fragmentation has been achieved [98], and protonation and 
deprotonation have been reported to be the favoured ionisation process [104,105,106]. AP-
DIOS uses the AP-MALDI source design. AP-MALDI/MS and AP-DIOS/MS have high 
throughput and automation capability for the rapid analysis of samples. The rate of analysis is 
currently limited by the data acquisition systems. 
 
2.3.2. Applications 
 
Table 3 presents selected LC–MS applications, and their operational parameters, involving 
the analysis of the substances of interest of this study. Except for the information-dependant 
acquisition (IDA) method of Decaestecker et al.[107], the methods are targeted at identifying 
and/or quantifying predefined compounds. LC, or some separation is commonly used together 
with ESI although, e.g. Weinmann and Svoboda [108] successfully quantitated illicit drugs in 
serum and urine using only solid-phase extraction (SPE) and flow-injection analysis 
(FIA)/ESI/MS/MS. And Selby et al. [109] successfully quantitated the alkaloids present in 
illicit heroin samples by FIA/ESI/MS/MS. Nowadays, some separation in combination with 
ESI is nevertheless considered essential owing to the problems of direct sample introduction. 
The problems arise from the matrix, which can suppress the ionisation efficiency. The 
suppression can be unpredictable and even originate from compounds lacking electrospray 
response [110]. In addition, compounds that have the same mass equivalent precursor ion can 
be problematic if they are not separated before the mass analysis. The CE methods are not 
included in Table 3, although a number of applications of CE/MS in forensic analysis have 
been published [111–115]. 
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Vacuum-MALDI has been used in analysing benzodiazepines quantitatively from tablets 
[116], vacuum-DIOS has been applied to the analysis of small molecules, such as 
catecholamines [117]. Vacuum-MALDI [118] and vacuum-DIOS [119,120] have been 
applied in forensics only in the analysis of synthetic polymers. AP-MALDI [121] and AP-
DIOS [122,123] have been used for both qualitative and quantitative analysis of small drug 
and biogenic molecules, but so far they have not been used in practical casework in forensic 
drug analyses. 
 
Many recent reviews [15,124–130] have described the operational parameters and 
applications of LC–MS in analysing drugs of abuse and other toxic compounds in forensic 
toxicology and related areas. Only methods reported in the last four years are included in 
Table 3. Unfortunately LC–MS methods continue to be underrepresented in the analysis of 
drug seizure samples[2,3,131,132]. In the three latest reviews of this area [3,131,132], less 
than 3% of the references cover atmospheric pressure ionisation–, TS–, particle beam– or fast 
atom bombardment ionisation–MS techniques. Applications of LC–MS in forensic toxicology 
can be considered comparable in many respects. The different matrix, the higher 
concentration of the analytes and the absence of metabolites are the main differences between 
analyses in forensic toxicology and analyses of drug seizures. The legal demands are the 
same.  
 
Table 3 shows that the reversed-phase (RP) octadecylsilyl (C18) column is still the most 
widely used analytical column with MS detection. LC methods are continuing to evolve, 
however, because the high selectivity of tandem mass spectrometry, accurate mass 
measurement and developments in acquisition rates are making the complete chromatographic 
separation of different compounds unnecessary. The development of pumps suitable for fast 
gradient chromatography, high-throughput columns like short and monolithic columns and 
the fast ultra-high pressure separations allow shorter LC run times. For example, Jeanville et 
al. [133] quantitated cocaine and its primary metabolites in 3.2 minutes using a 3 cm column, 
and Wu et al.[134] separated six benzodiazepines within 90 s using ultrahigh pressure LC–
TOF. Such short analysis times mean that the sample preparation step can become the rate-
limiting step, particularly in the analysis of biological samples.  
 
The fast development of LC–MS instrumentation is clearly evident in the recent reviews, as in 
Table 3. By 1997 the atmospheric pressure ionisation interfaces ESI and APCI were 
beginning to find wider use, and by 2000 they were virtually the only ionisation techniques in 
use. Although the mass analysers used in routine applications are still mostly single 
quadrupoles (Q), triple quadrupoles (QQQ), and quadrupole ion traps (QIT), now the use of 
TOF and quadrupole time-of-flight (QTOF) analysers is increasing. Recently, for example, 
TOF was used in an identification of street drugs based on accurate mass and a target library 
of exact monoisotopic masses [135]. The quantitation was performed with 
chemiluminescence nitrogen detection (CLND) and the use of primary reference standards 
was, therefore, avoided with both detectors. While the widely used single quadrupole 
technique has limitations, it has proven to be useful in certain applications. The triple 
quadrupole instrument operated in MRM mode is a more sensitive technique than QIT or 
TOF, as is also seen in Table 3. In QIT and TOF, however, a full spectrum is recorded with 
better sensitivity in comparison to triple quadrupoles. Owing to its very high acquisition rate, 
QTOF can be the most sensitive technique for the acquisition of product ion spectra [136].  
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Table 3. Operational parameters of selected LC–MS methods for analysing illicit drugs published in 2000–2004. The compounds of interest were 
given special emphasis in the selection of methods. 
Compounds Matrix Sample 
preparation 
Separation Detection and 
Details 
LOD (ng/ml) Linearity 
(ng/ml) 
Ref. Year 
Psilocin, psilocybin Honey MeOH 
extraction 
LC: C18: (125 x 3 mm), ACN/50 mM NH4OCOH pH 3.0 5/95, 
0.6 ml/min 
APCI+,  
Q 
MRM, 
[M+H]+s 
n.d. n.d. [137] 1997 
Psilocin Mush-
rooms 
Ethyl acetate 
extraction, 
Derivatisation 
DBD-Pro-COCl, 
Bufotenin ISTD 
LC: RP-18 (100 x 2 mm, 3 µm) 50 mM NH4OAc/ACN 
(73/27), 0.15 ml/min, inj. V 5 µl, runtime 35 min 
ESI+, 
QIT 
SIM 
[M+H]+ 
and MRM
LOQ: 
6.3 ng/mg 
mushroom 
1.6–4.08 [138] 2004 
15 1,4-
benzodiazepines, 
+metabolites 
Stds, 
hair 
Soxhlet 
(hair), ESTD 
LC: C18 (150 x 4.6 mm)+similar guard (30 mm), 
H2O/ACN/MeOH 30/5/65 (15 benzos) ACN/H2O 65/35 (for 
indiv. cmpds+metab.), 0.25 ml/min, inj. V 20 µl, runtime 18 
min. Also CE methods developed. 
ESI+,  
QIT 
MRM, 
[M+H]+ 
16.7 
(temazepam) 
22.5–150  [139] 1999 
Temazepam, + 6 
other 
benzodiazepines 
Buffer 
solution, 
urine, 
serum  
In-tube 
SPME, 
ESTD 
LC: C18 (50 x 2.1 mm, 3 µm), isocr. 50 mM NH4OAc/MeOH 
40/60, 0.3 ml/min, T = 25°C, run time 12 min 
ESI+,  
Q 
SIM, 
[M+H]+ 
1.0 
(temazepam) 
2.0–500 
(temazepam)
[140] 2000 
Temazepam, + 3 
other 
Dog 
plasma 
Automated 
SPE, d5-
diazepam 
ISTD 
LC: C18 (50 x 2.1 mm, 5 µm), A: 0.01M NH4OAc, B: ACN, 0-
3 min 30% B, 3-5 min 30-100% B, 0.25 ml/min, ambient T, 
run time 5 min 
ESI+,  
QQQ 
MRM, 
[M+H]+ 
0.3 (LOQ) 0.3–150  [141] 2001 
11 benzodiazepines+ 
metab. 
Urine Hydrolysis+ 
filtration+on-
line SPE 
LC: C18 (150 x 1.5 mm, 5 µm), 10 mM NH4OAc/ACN, non-
linear gradient with elution of trapped analytes and separation, 
0.15 ml/min,  T = 30°C, run time 38 min 
APCI+,  
Q 
SIM, 
[M+H]+ 
2–10 (SIM), 
20–50 (scan) 
2–10–500 [142] 2002 
Temazepam, + 9 
other 
benzodiazepines 
Plasma LLE,  
d-analogues 
ISTD 
LC: RP phenyl column (150 x 2.1 mm, 5 µm), A: 
ACN/MeOH/20 mM NH4OAc 10/10/80, B: ACN/20 mM 
NH4OAc 95/5, nonlinear, stepped gradient, 0.25 ml/min, inj. V 
10 µl, run time 15 min 
ESI+,  
QQQ 
MRM, 
[M+H]+s 
0.4 1–800  [143] 2002 
Benzodiazepines, 
buprenorphine, LSD, 
+ metabolites 
Blood, 
urine 
LLE or SPE, 
d-analogues 
ISTD 
LC: n.d. n.d. scan, 
MRM 
10, heroin 
metabolites, 
blood, <0.1, 
buprenorphine, 
urine  
n.d. [144] 2002 
Temazepam, 3 other 
compounds 
Plasma High-flow 
on-line extr., 
alpratzolam 
ISTD  
LC: monolithic C18 (100 x 4.6 mm), A: 0.1% FA, B: 
ACN+0.1% FA, 0-1.2 min 10-90% B, 4 ml/min, split 
0.4ml/min to MS 
 
ESI+,  
QQQ 
MRM, 
[M+H]+ 
n.d. 2.5–5000  [145] 2003 
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Table 3. (Continued) 
Compounds Matrix Sample 
preparation 
Separation Detection and 
Details 
LOD (ng/ml) Linearity 
(ng/ml) 
Ref. Year 
Temazepam + 32 
benzodiazepines/ 
metabolites 
Blood LLE 
Methyl-
bromazepam 
ISTD 
LC: C18 (150 x 2.1 mm, 3.5 µm) A: 0.006 FA, pH 3, B: MeOH, 
0–5 min 30-40% B, 5–25 min 40-50% B, 25–30 min 50-60% 
B, 30 –35 min 60% B, 36–45 min 30% B, 0.2 ml/min. Inj. V 50 
µl, T=30°C, cycle time 45 min 
APCI+, 
QIT 
SIM 
[M+H]+or 
MRM 
0.1–12.6 5–2000 
(temaze-
pam) 
[146] 2004 
Temazepam + 22 
benzodiazepines + 4 
other 
Plasma LLE 
4 d-analogue 
ISTDs 
LC: Spherical RP (125 x 2.0 mm, 6 nm pore size) + similar 
guard column, A:5 mM NH4formate, pH 3, B: ACN, gradient 
and flow-rate programming, inj. V. 5 µl, runtime 10 min. 
APCI+,  
Q 
Scan 
(screening) 
SIM 
(quantit.) 
5.0 (scan), 10 
(SIM;LOQ) 
(temazepam) 
10–1250 
(temaze-
pam) 
[147] 2004 
Temazepam + 3 
other 
benzodiazepines 
Blood Restricted- 
access SPME 
LC: C18 (50 x 4.6 mm, 5 µm)+ C18  (10 x 4.6 mm) guard, 
H2O/MeOH, 0.6 ml/min, runtime 15 min 
ESI+, Q SIM 
[M+H]+ 
30 
(temazepam) 
50–1000 [148] 2004 
DMeA, + 
metabolites: MA, 
AM 
Urine SPE, ESTD LC: SCX col. (150 x 2.0 mm) 5 mM NH4OAc, pH 4.0/ACN 
35/65, 0.2 ml/min, runtime 25 min 
ESI+,  
Q 
SIM, 
[M+H]+ 
50 (AM), 10 
(MA) 
100–5000 
(AM), 
50–5000 
(MA) 
[149] 2000 
AM, MA, MDA, 
MDMA, MDEA +11 
other 
 
Serum SPE, d-
analogue 
ISTDs 
LC: C18 (125 x 3 mm, 4 µm), ACN/50 mM NH4OCOH, pH 3.0 
25/75, 0.3/0.4/0.8 ml/min depending on compound 
APCI+,  
Q 
SIM, 
[M+H]+s 
+ 1 or 2 
fragments 
1.0–2.0 5–500  [150] 2000 
AM, + 1 other Hair Digestion + 
LLE, 
d-analogue 
ISTDs 
LC: C18 (300 x 2.0 mm, 5 µm), isocr. 0.1% FA/MeOH 80/20 
(AM), runtime 3.0 min 
 
ESI+,  
QQQ 
MRM, 
[M+H]+s 
n.d. 16–8000  [151] 2001 
AM, MA, MDA, 
MDMA, MDEA 
Plasma LLE, 
d-analogue 
ISTDs 
LC: C18 (100 x 2.1 mm, 3.5 µm), 10 mM NH4OAc/ACN 75/25, 
isocratic, 0.3 ml/min, inj. V 10 µl, runtime 4.5 min 
 
ESI+,  
QQQ 
MRM, 
[M+H]+s 
n.d. 0.1–500 [152] 2001 
AM, MA, MDA, 
MDMA, MDEA  
Saliva LLE, 
d-analogue 
ISTDs 
LC: C18 (100 x 2.1 mm, 3.5 µm), 10 mM NH4OAc/ACN 90/10, 
isocratic, 0.3 ml/min, inj. V 10 µl, runtime 3.5 min 
  
ESI+,  
QQQ 
MRM, 
[M+H]+s 
1.0 (in saliva) 0.1–500  [153] 2001 
AM, MA, MDA, 
MDMA, MDEA, 
morphine, cocaine, + 
2 other 
Oral 
fluid 
SPE, 
MDMPA, 2´-
methylcocaine 
ISTD (3 
ISTDs) 
LC: RP phenyl column (100 x 2.1 mm, 3 µm) and phenyl guard 
(7.5 x 2.1 mm), MeOH+10 mM NH4OCOH/10 mM 
NH4OCOH, pH 5 6 –41.2% MeOH in 20 min, 0.2 ml/min, total 
runtime 28 min 
 
ESI+, 
QTOF 
MRM, 
[M+H]+s , 
morphine 
not 
fragmented 
0.22–1.07 2.0–100 
 
[154] 2002 
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Table 3. (Continued) 
Compounds Matrix Sample 
preparation 
Separation Detection and 
Details 
LOD (ng/ml) Linearity 
(ng/ml) 
Ref. Year 
DMeA, + 
metabolites: MA, 
AM 
Urine Direct 
injection, 
ESTD 
LC: Highly cross-linked polyvinyl alcohol gel (Asahipak GS-
320HQ), (300 x 7.6 mm, 1 µm prefilter), ACN/20 mM 
NH4OAc, pH 8.5 30/70, 0.6 ml/min, split 0.07 ml/min to MS, 
runtime 60 minutes 
Chiral LC for DMeA: Chiral DRUG (150 x 2 mm, 1 µm 
prefilter), ACN/20 mM NH4OAc, pH 5, 0.1 ml/min, runtime 30 
min 
ESI+,  
Q 
Scan 
(qual), 
SIM, 
(quant), 
[M+H]+s 
20 (MA), 60 
(AM) (SIM) 
60–3000 
(MA), 
180–9000 
(AM) 
[155] 2002 
AM, MA, EP, 
MDMA, MDA, 
MDEA 
Plasma, 
oral 
fluid 
LLE,  
d-analogue 
ISTDs 
LC: C18 (100 x 2.1 mm, 3.5 µm), 10 mM NH4OAc/ACN 75/25, 
0.3 ml/min, inj. V 10 µl, runtime 4 min, total analysis time 20 
min (including sample preparation) 
ESI+,  
QQQ 
MRM, 
[M+H]+ 
0.2–2.0  0.5–500  [156] 2003 
AM, MDMA, 
cocaine, 9 other 
drugs 
Seized 
drugs 
Dissolution to 
MeOH, dil. 
with MeOH/ 
0.1% FA, 
no standard 
LC: C18 (100 x 20 mm, 3 µm) + 4 x 20 mm precolumn, A: 5 
mM NH4OAc in 0.1% FA, B: 5 mM NH4OAc in ACN, 0–10 
min 10–40% B, 10–13.5 min 40–75% B, 13.5–16 min 75–80% 
B, 16–19 min 80% B, 0,3 ml/min, T=40°C, inj. V 10 µl, total 
cycle time 24 min (TOF); A: 0.1% FA, B: MeOH, 0–7min 10–
40% B, 7–12 min 40–75% B, 12–15.5 75–90%B, 15.5–19 90% 
B, 0.25 ml/min, T=40°C, inj. V 10 µl, total cycle time 26 min 
ESI+, 
TOF  
Quant. 
CLND 
Exact 
monoisot. 
mass 
(TOF) 
equimolar 
N response 
(CLND) 
n.d. n.d. [135] 2004 
Pentobarbital, 
(Phenobarbital as 
ISTD) 
Dog 
food 
SPE, 
phenobarbital 
ISTD 
LC: Polystyrene-divinylbenzene (150 x 2.1 mm, 5 µm) A: 
water, B: ACN 0-4 min 20% B – 50% B, 4-7 min 50% B, step 
to 90% B, 7-9 min 90% B, 0.3 ml/min, total cycle time 25 min 
APCI-, 
QIT 
(no 
signal in 
APCI+/ 
ESI+, 
ESI- yes) 
MS/MS  
[M-H]-s 
scan+SIM
40 
(pentobarb.) 
10–400  [157] 2000 
Cocaine, + 1 metab. Urine 1/10 dilution, 
d3-cocaine 
ISTD 
LC: PFPP bonded silica column (30 x 2.1 mm, 5 µm), ACN/5 
mM NH4OCOH, pH 3.0, 90/10, 0.6 ml/min, inj. V 10 µl, 
runtime 4.5 min 
ESI+,  
QQQ 
MRM, 
[M+H]+s 
0.16 1.0–1000  
LOQ 5.3 
[158] 2000 
Cocaine, + 15 
metab. 
Meco-
nium 
LLE + SPE, 
d3-cocaine 
ISTD 
LC: C8 (150 x 2.1 mm, 5 µm), A:20 mM NH4OAc, pH 2.7, 
B:MeOH/ACN 50/50, stepped gradient, 0.27 ml/min, T=38°C, 
run time 20 min, total cycle time 25 min 
ESI+,  
QQQ 
MRM, 
[M+H]+s 
1.0  1.0–1000  [159] 2000 
Cocaine, + 12 
metab. 
Blood, 
amniotic 
fluid, 
placental 
& fetal 
tissue 
SPE,  
d3-cocaine 
ISTD 
LC: C8 (150 x 2.1 mm 5 µm), A: 20 mM NH4OAc, B: 
MeOH/ACN 50/50, 0- 2 min 0% B, 2-7 min 0-15% B, 7-15 
15% B, 15-23 min 15-100% B, 0.27 ml/min, T=37 °C, runtime 
23 min 
 
ESI+,  
QQQ 
MRM, 
[M+H]+s 
0.5 (cocaine) 10–250  [160] 2001 
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Table 3. (Continued) 
Compounds Matrix Sample 
preparation 
Separation Detection and 
Details 
LOD (ng/ml) Linearity 
(ng/ml) 
Ref. Year 
Cocaine, + 1 metab. aCSF In vivo 
microdialysis 
LC: C18 (125 x 3 mm, 5 µm), + guard col., A: 0.05% HOAc, 
pH 3.55, B: ACN+0.05% HOAc, 0-4 min 15%B, 4-10 min 15-
65% B, 0.5 ml/min, inj. V 10 µl, total cycle time 20 min 
ESI+,  
Q 
SIM, 
[M+H]+s 
1.5 (cocaine) 3–3000  [161] 2001 
Cocaine, + 2 metab. Urine SPE on-line, 
d-analogue 
ISTDs 
LC: Allure basix® (30 x 2.1 mm, 5 µm) + guard col., A: 50 
mM FA+100mM NH4OCOH in water, B: ACN/acetone 60/40, 
total runtime 3.2 min  
ESI+,  
QQQ 
MRM, 
[M+H]+s 
0.25 
(cocaine) 
7.5–1000  [133] 2001 
Cocaine, + 4 metab. Hair Digestion + 
SPE, 
d-analogue 
ISTDs 
LC: Metasil basic (100 x ? mm, 3 µm), isocr. 0.1% FA/MeOH 
75/25, 0.25 ml/min, T=30°C, runtime 15 min 
ESI+,  
Q 
SIM, 
[M+H]+s 
n.d. 7.2–18000 [162] 2001 
Cocaine, + 1 other Plasma SPE, 
d-analogue 
ISTDs 
LC: C18 (100 x 2.0 mm, 5 µm), isocr. MeOH/0.1% FA 50/50, 
0.15 ml/min, inj V. 20 µl, runtime 5 min 
 
APCI+, 
QQQ 
MRM, 
[M+H]+s 
n.d. 2.5–750  [163] 2001 
Cocaine, + metab. Plasma SPE, 
d-analogues 
ISTD 
LC: C8 (150 x 2.1 mm, 5 µm), A: 20 mM NH4OAc, B: 
MeOH/ACN 1/1, 0-1 min 1% B, 1-3 min 1-80% B, 3-15 min 
80% B, 0.3 ml/min, ambient T, 1/7 split, runtime 15 min 
ESI+,  
QQQ 
MRM, 
[M+H]+s 
4.1 (cocaine) 5–1000  
LOQ 14.4 
[164] 2001 
Cocaine, + 3 
metabolites 
Plasma  SPE,  
d-analogue 
ISTDs 
LC: C18 (100 x 2 mm, 5 µm), 0.1% FA/MeOH 55/45, 0.15 
ml/min, runtime 5 min 
 
ESI+ or 
APCI+, 
QQQ 
MRM, 
[M+H]+ 
2.5 (LOQ) 2.5–750 
(n.d.) 
[165] 2003 
Cocaine, + 3 
biogenic amines 
aCSF Microdialysis LC: C18 (150 x 2.1 mm, 3 µm or 150 x 2.0 mm, 3 µm), A: 0.1% 
FA, B: ACN+0.1% FA 0–0.5 min 0% B, 0.5–4.0 min 0–100% 
B, 0.3 ml/min, T=40°C, inj. V 10 µl 
ESI+. 
QQQ 
MRM 
[M+H]+ 
0.001 or 
0.0001 (dep. 
on mass 
analyser) 
5 decades [166] 2004 
Morphine, MDMA, 
cocaine, 14 other 
(GUS) 
Urine LLE, 
Butorphanol 
ISTD 
LC: C18 (100 x 2.1 mm, 3.5 µm), from 90% H2O/MeOH/ACN 
(82/9/9) + 0.045 M NH4OAc to 90% MeOH/ACN (18/41/41) + 
0.045 M NH4OAc, 0.2 ml/min, inj. V 50 µl, total runtime 23 
min 
ESI+, 
QTOF 
MRM, 
[M+H]+s 
(mostly) 
(IDA) 
n.d. 200–
2/4000  
200–2000 
(cocaine) 
[107] 2000 
Morphine, + 6 other 
opiates 
Blood SPE,  
nalorphine 
ISTD 
LC: C18 (150 x 4.6 mm, 3 µm), A: 0.1% FA, B: MeOH, 0 – 2 
min 5% B, 2 –10 min to 90% B, until 20 min in 90% B, 0.5 
ml/min, T=50°C, inj. V 10 µl, runtime 20 min 
ESI+,  
QIT 
MRM, 
[M+H]+s 
LOQ <10 50–750  [167] 2001 
Morphine, + 2 
metab. 
Plasma  Automated 
SPE,  
d-analogue 
ISTDs 
LC: Silica (50 x 3.0, 5 µm), H2O/ACN/trifluoroacetic acid 
9/91/0.01 Inj. V 5 µl, 0.7 ml/min, runtime 3.5 min 
 
 
ESI+,  
QQQ 
MRM, 
[M+H]+s 
286152 
0.5 (LOQ) 0.5–50 [168] 2002 
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Table 3. (Continued) 
Compounds Matrix Sample 
preparation 
Separation Detection and 
Details 
LOD (ng/ml) Linearity 
(ng/ml) 
Ref. Year 
Morphine, cocaine, 
propoxyphene, + 27 
other 
drugs/metabolites 
Oral 
fluid 
ACN protein 
precipitation, 
14 d-
analogue 
ISTDs 
LC: Ether-linked phenyl with polar end-capping, (150 x 2.0 
mm, 4 µm)+ similar guard (4.0 x 2.0 mm), A:10 mM 
NH4formate+0.001% FA, pH 4.5, B: ACN, 0-13 min 5-26% B, 
13-22 min 26-90% B, 22-24 min 90% B, 24-27 min 90-5% B, 
0.3 ml/min, inj V. 50 µl, T=25°C, total analysis time 35 min 
APCI+, 
QQQ 
MRM, 
[M+H]+ 
 
0.5, 5.0 
(propoxy-
phene) 
1–500 or  
10–500 
(propoxy-
phene)  
[169] 2003 
Morphine, + gluc. Plasma SPE  
d3-ISTD 
LC: C18 (150 x 2.1 mm, 5 µm) and C8 guard (4 mm x 2 mm), 
isocratic ACN/MeOH/10 mM OCOH, pH 3, 2.2/2.5/95%, flow 
rate 0.2 ml/min, runtime 10 min 
ESI+,  
Q 
SIM 
[M+H]+ 
0.25 
(signal/noise 
2/1) 
0.5–200  [170] 2003 
Morphine, cocaine + 
gluc., + 4 other 
Meco-
nium 
SPE 
Nalorphine 
ISTD 
LC: C8 (150 x 4.6 mm), 1% HOAc/ACN 97/3 to 73/27 in 11 
min, 1 ml/min, inj. V 20 µl, T=30°C, runtime 15 min, cycle 
time 25 min 
ESI+,  
Q 
SIM 
m/z 286, 
227, 209 
m/z 304, 
212, 182 
1.2 
(morphine), 
0.9 (cocaine) 
5.0–1000  [171] 2003 
Morphine, MDMA, 
cocaine, 14 other 
(GUS) 
Blood LLE, SPE, 
Butorphanol 
ISTD 
LC: C18 (100 x 2.1 mm, 3.5 µm), from 100% H2O/MeOH/ACN 
(80/10/10) + 5 mM NH4OAc (=A) to 50% H2O/MeOH/ACN 
(20/40/40) + 5 mM NH4OAc (=B), in 7 min and 7 min hold + 
1.5 min 100% B. 0.3 ml/min, inj. V 25 µl, total run time 24 min
ESI+, 
QTOF 
MRM, 
[M+H]+s 
(mostly) 
(IDA) 
60–160 e.g. 
for morphine, 
8–16 for 
cocaine 
modifica-
tions of 
ref. [107] 
[172, 
173] 
2004 
Morphine + 2 
glucuronides 
Dog and 
monkey 
plasma 
SPE, 
nalorphine 
ISTD 
LC: C18 (150 x 2.1 mm, 5 µm), ACN/0.05% HOAc (1/24) or 
MeOH/0.01% FA (1/19), T=40°C, 0.1 ml/min, inj. V 10 µl, 
runtime 9 min 
ESI+, 
QQQ 
MRM 
[M+H]+ 
0.5 (LOQ) 0.5–50 or 
100 
[174] 2004 
Morphine, 
buprenorphine, 
temazepam, 
phenobarbital, AM, 
MDMA, 64 other 
stimulants 
Plasma Protein 
precipitation 
LC: C18 (50 x 2.0 mm, 3µm), C8 (10 x 2.0 mm) guard column, 
A: 10 mM NH4OAc+5% ACN, pH 5.0, B: 10 mM 
NH4OAc+90% ACN, pH 5.0, 0–2 min 0–20%B, 2–12 min 20–
60%B, 12–14 min 60–100%B, 14–16 min 100%B, , 0.2 
ml/min, inj. V 20 µl; two injections: screening and 
confirmation, total cycle time 21 min 
ESI+, 
QIT, 
DAD 
1) MS: 
[M+H]+ 
2) in-
source 
CID 
230–300 
nm 
5 (AM, mor-
phine, temaze-
pam), 1.0 
(buprenor-
phine), 0.5 
(MDMA), 
phenobarbital 
only DAD  
n.d. [175] 2004 
Morphine, cocaine, 
LSD, 9 other drugs 
Plasma, 
urine 
SPE, d-
analogue 
ISTDs 
LC: C18 (150 x 2 mm, 3 µm)+ polar-RP guard, A: 4 mM 
NH4OAc, pH 4.6, B: ACN, 0–1 min 0%B, 1–13 min 0–60%B, 
13–15 min 60%B, 15–17 min 60-0%B, 17–23 min 0%B, post 
column: ACN 0.05 ml/min (basic drugs), phenylhexyl column 
(50 x 2.0 mm, 3 µm) + Polar-RP guard (4 x 2.0 mm), A: 5 mM 
NH4OAc, pH 6.5, B: ACN, 0–0.4 min 30% B, 0.4–7.8 min 30–
90%B, 7.8–8.2 min 90%B, 8.2–8.5 90–30%B, 8.5–11 min 
30%B, (Cannabinoids), 0.25 ml/min, T=40°C, inj. V 20 µl 
ESI+, 
QQQ 
MRM 
[M+H]+ + 
2 qualif. 
ions 
4.0 
(morphine), 
1.5 (cocaine)  
6.3–250 
(morphine) 
4.7–500 
(cocaine) 
[176] 2004 
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Table 3. (Continued) 
Compounds Matrix Sample 
preparation 
Separation Detection and 
Details 
LOD (ng/ml) Linearity 
(ng/ml) 
Ref. Year 
Morphine, cocaine, 7 
other 
Hair LLE, SPE, 
d-analogue 
ISTDs 
LC: C18150 x 2.0 mm, 4 µm) c18 (4 x 2.0 mm) guard, A: 10 
mMNH4OAc+0.001% FA, pH 4.5, B: ACN, 0–20 min 10–
90%B, 20–22 min 90%B, 0.2 ml/min, T=30°C, Inj. V 20 µl, 
cycle time 30 min 
APCI+, 
QQQ 
MRM 
[M+H]+ 
16.6 
(morphine),  
3.4 (cocaine) 
33.2–
10000 
(morphine) 
6.8–200 
(cocaine) 
[177] 2004 
LSD, iso-LSD, + 7 
metab. 
Blood, 
plasma, 
urine 
LLE, d3-LSD 
ISTD 
LC: Spherisorb 5 RP 8S C8 (100 x 2.1 mm, 5 µm), 40% 
H2O+60% ACN + 0.1% FA+ 2 mM NH4OCOH, 0.4 ml/min, 
runtime 8 min 
ESI+,  
QQQ 
MRM, 
[M+H]+; 
neutral loss 
scan for 
metab. ID 
0.2 (LOQ) 0–4.0  [178] 2001 
LSD Urine LLE, 
d3-LSD ISTD 
LC: C18, other conditions not reported. ESI+,  
Q 
n.d. 0.02 0.05–10  [179] 2001 
Buprenorphine, + 2 
metab. 
Plasma SPE, d-
analogue 
ISTDs 
LC: Inertsil ODS-3 (100 x 3 mm, 3µm), A: 2 mM NH4OCOH 
+ 0.1% FA, B: ACN/H2O 99.5/0.5 +2 mM NH4OCOH + 0.1% 
FA, 0-0.1 min 16% B, 0.1-5.1 min 30% B, 5.1-7.6 min 30% B, 
total runtime 12.7 min 
ESI+,  
QQQ 
MRM 
Surviving 
[M+H]+ 
0.1 (LOQ) 0.1–50  [180] 2001 
Buprenorphine, 
cocaine, dextro-
propoxyphene, DXM, 
LSD, MDMA, MA, 
morphine, temazepam 
+ 229 other 
Blood LLE 
Dibenzepine 
and enalapril 
ISTDs 
LC: C18 ACN/10 mM NH4OAc, pH 3.2 with FA 20/80 to 100/0 
in 10 min, 3 min isocratic, 0.2 ml/min, inj. V 30 µl, T=35°C, 
run time 13 min, cycle time 18 min  
 
ESI+,  
QQQ 
MRM,  
[M+H]+s  
10, < 20, <20, 
<20, <20, 20, 
50, 100, <20 
n.d. [28] 2003 
Buprenorphine, 1 
metabolite 
Plasma SPE 
clonazepam 
ISTD 
LC: C18 (55 x 4 mm, 3 µm), MeOH/50 mM NH4OAc, pH 4.5 
50/50, 0.8 ml/min, T=30°C 
APCI+, 
QQQ 
MRM 
[M+H]+ 
(surviving 
parent 
ion) 
0.002, 
0.01 (LOQ) 
0.01-5.0 [181] 2003 
AM, MDMA, 
buprenorphine, LSD, 
morphine, 
phenobarbital, 
psilocybin, 
temazepam, 6 other 
Seized 
drugs 
LLE 
ESTD 
LC: C18 (50 x 4.6 mm, monolith), A: 0.1% FA/MeOH+0.1% 
FA 95/5, B: MeOH+0.1% FA/0.1% FA 95/5, 0-0.5 min 5–50% 
B, 0.5-2.5 min 50–100%B, 2.5 ml/min, inj V. 50 µl, T=30 °C, 
runtime 2.5 min, cycle time 5 min 
ESI+,  
QIT 
MRM, 
[M+H]+s 
10–50  100–
30000  
I 2003 
Special abbreviations used in the table: DMeA: Dimethylamphetamine; EP: Ephedrine; MDMPA: 3,4-Methylenedioxymethylpropylamphetamine; aCSF: Artificial 
cerebrospinal fluid; Gluc: Glucuronide/-s; GUS: General unknown screening; LLE: Liquid-liquid extraction; SPE: Solid phase extraction; DBD-Pro-COCl: 4-(2-
Chloroformylpyrrolidin-1-yl)-7-(N,N-dimethylaminosulfonyl)-2,1,3-benzoxadiazole; ESTD: External standard; Q: Single quadrupole; QQQ: Triple quadrupole; CLND: 
Chemiluminescence nitrogen detection; LOQ: Limit of quantitation; n.d.: Not determined/reported
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3. AIMS OF THE STUDY  
 
The aims of this study were to evaluate the applicability of liquid chromatographic, liquid 
chromatography–electrospray ionisation/mass spectrometric, and atmospheric pressure laser 
desorption ionisation/mass spectrometric techniques in qualitative and quantitative analyses 
of drugs of abuse in drug seizures.  
 
The more specific aims of the research were 
 
• to study the applicability of fast liquid chromatography–electrospray 
ionisation/tandem mass spectrometry (LC–ESI/MS/MS) and library searching to fast 
detection, identification and quantitation of forensically relevant compounds with different 
physical and chemical properties (I), 
 
• to study the mass spectrometric behaviour of mass equivalent isomers and isobaric 
substances of 3,4-MDMA and to develop a fast confirmation method for the presence of 3,4-
MDMA in order to quickly distinguish it from the non-controlled substances by fast LC–
ESI/MS/MS and library searching (II), 
 
• to evaluate in a preliminary way the feasibility of atmospheric pressure matrix 
assisted laser desorption ionisation (AP-MALDI) and atmospheric pressure desorption 
ionisation on silicon (AP-DIOS) mass spectrometry for fast detection and identification of 
small drug molecules encountered in forensic drug seizures (III), 
 
• to study the effect of eluent composition on enantiomer separation of selected basic 
drugs using vancomycin and native β-cyclodextrin chiral stationary phases and to develop 
chiral liquid chromatographic separation methods for forensic purposes using ESI/MS 
detection (IV). 
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4. MATERIALS AND METHODS  
 
The major experimental features are described in this section. For more detailed descriptions 
the reader is referred to the original publications I–IV. 
 
4.1. Chemicals 
 
The standards and chemicals that were used are listed in Table 4. The structures of the studied 
compounds are presented in Figure 1. 
 
4.2. Instrumentation 
 
All instrumentation is presented in Table 5. Helium (4.6, 99.996%) was used in the ion traps 
as damping and collision gas. 
 
The LC separations in studies I and II were carried out with a Chromolith Speedrod monolith 
column (50 x 4.6 mm, C18 RPe Merck, Germany). The chiral LC separations in study IV were 
carried out with Chirobiotic V vancomycin chiral column and Cyclobond I 2000 native β-
cyclodextrin chiral column (both 150 x 4.6 mm, 5 µm particle size, Advanced Separation 
Technologies Inc., USA). The column eluent was split and one tenth was directed to MS. In 
study IV, one tenth of the eluent was directed to MS and nine tenths to a diode array detector 
(DAD). 
 
The control software versions were Chemstations 08.03 (I) and 09.04 (II, IV) for the LC and 
LC/MSD Trap software versions 4.1 (I) and 4.2 (I, II, IV) for the MS. The control software 
versions used in III were EsquireControl version 5.0 for the MS and Target software version 
3.4 for the AP-MALDI source.  
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Table 4. Standard compounds and chemicals used in the study. 
Standard/chemical Purity and comments Supplier/Manufacturer Paper 
α-Cyano-4-hydroxycinnamic 
acid (α-CHCA) 
Purum grade, ≥ 99% Sigma-Aldrich (USA) III 
β-Hydroxy-3-methylfentanyl Standard United Nations (Austria) III 
β-Hydroxyfentanyl Standard United Nations (Austria) III 
α-Methylfentanyl  Standard United Nations (Austria) III 
17 isomeric and isobaric 
substances to 3,4-MDMA  
Synthesised reference material, 
purified by recrystallisation 
[182] 
Dr. L.A. Aalberg, Auburn 
University (USA) 
II 
3-Methylfentanyl (3-MF) Standard United Nations (Austria) III 
Acetic acid Analytical grade Riedel-de Haën (Germany) IV 
Acetonitrile LC grade Rathburn (Scotland) II, IV 
Acetylfentanyl Standard United Nations (Austria) III 
Alfentanil  Standard United Nations (Austria) III 
Ammonium acetate (NH4OAc) Reagent plus grade  Sigma-Aldrich (USA) IV 
Amphetamine Standard Sigma (USA) or Lipomed 
AG (Switzerland) 
I, III, IV 
Buprenorphine Reference material USP Inc. (USA) I 
Clenbuterol Standard Sigma (USA) I 
Dextropropoxyphene Standard Sigma (USA) IV 
Ethanol AA Primalco Ltd (Finland) III 
Fentanyl  Standard Sigma (USA) III 
Formic acid Analytical grade Merck (Germany) I 
Hydrofluoric acid 48 % (w/v) in water, 99.99+% Sigma-Aldrich (Germany) III 
Isopropyl alcohol LC grade Rathburn (Scotland) IV 
Levomethorphan Standard University Pharmacy 
(Finland) 
IV 
Levopropoxyphene Standard USP Inc. (USA) II 
LSD Standard USP Inc. (USA) I 
MDA Standard United Nations (Austria) III, IV 
MDEA Standard United Nations (Austria) III, IV 
MDMA Standard RBI (USA) or United 
Nations (Austria) 
I – IV 
Metandienone Standard Steraloids Inc. (USA) I 
Methamphetamine Standard Lipomed AG (Switzerland) III, IV 
Methanol LC grade Rathburn (Scotland) I, IV 
Morphine Standard  University Pharmacy 
(Finland) 
I 
Nandrolone Standard Steraloids Inc. (USA) I 
Norephedrine Standard Knoll AG (Germany) III, IV 
PCA Standard Sigma (USA) III, IV 
Phenobarbital Standard Radian International (USA) I 
PMA Standard Lipomed AG (Switzerland) III, IV 
PMMA Standard Lipomed AG (Switzerland) III, IV 
Psilocybin Standard Lipomed AG (Switzerland) I 
Rasemethorphan Reference material University Pharmacy 
(Finland) 
IV 
Salbutamol Standard Sigma (USA) I 
Stanozolol Standard Sigma (USA)  I 
Sufentanil Standard United Nations (Austria) III 
Temazepam Standard Radian International (USA) I 
Testosterone Standard Fluka (Switzerland) I 
Triethylamine Analytical grade Fluka (Switzerland) IV 
Trifluoroacetic acid Analytical grade Sigma-Aldrich (USA) III 
Water Deionised, Milli Q 18 Ω Milli-Q, Millipore (USA) I – IV 
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Figure 1. Chemical structures of the studied compounds (continues). 
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Figure 1. Chemical structures of the studied compounds (continued). 
 
 
Table 5. Instrumentation used in the experimental work. 
Instrument Model/type Manufacturer Paper 
Liquid chromatograph LC 1100 with vacuum degasser, 
autosampler and DAD 
Agilent Technologies 
(USA) 
I, II, IV
ESI/ion trap mass 
spectrometer 
Agilent 1100 Series LC/MSD Trap, SL Agilent Technologies 
(Germany) 
I, II, IV
AP-MALDI/ion trap mass 
spectrometer 
Esquire 3000+ with AP-MALDI ion 
source 
Bruker Daltonics 
(Germany) and Agilent 
Technologies (USA) 
III 
Eluent flow splitter Accurate, with 1/10 and 1/100 split ratio LC Packings (USA) I, II, IV
Nitrogen generator  Model 75–72, for drying and/or 
nebulising gas 
Whatman (USA) I, II, 
III, IV 
pH meter MP 220, Inlab 422 electrode Mettler Toledo GmbH 
(Switzerland) 
IV 
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4.3. LC–ESI/MS/MS (I, II, IV) 
 
For LC–ESI/MS/MS, the stock solutions of drugs and synthesis products (1.0 to 7.0 mg/ml) 
were prepared in either methanol (MeOH) (I, IV) or in MeOH/H2O (1/1, v/v) (II). The 
dilutions for LC analyses were made with 0.1% formic acid (0.1% FA) (I) or deionised water 
(II, IV). Dilutions of 10–50 µg/ml were used in optimising the separations (I, II, IV) and in 
fragmentation studies of the compounds (I, II), and further dilutions were used in quantitative 
method development (I), testing of methods and determining the LODs (I, II, IV). 
 
The actual sample material (I, II, IV) was dissolved in MeOH, sonicated for 5–10 minutes, 
diluted with deionised water, and filtered (GHP Acrodisc, Pall Gelman Laboratory, Ann 
Arbor, USA) into autosampler vials. All solutions were stored at -20°C. In quantitative 
analyses the samples were weighed; in qualitative analyses an appropriate amount, e.g. 15 mg, 
was taken for the analysis. 
 
The achiral gradient LC separations (I, II) were initially modelled with chromatography 
simulation software (DryLab 2000 chromatography optimisation software v3.00.06, LC 
Resources Inc., Walnut Creek, CA, USA). The data obtained from two model runs with 
different linear gradients with all compounds to be separated was used as input data for the 
software. The final gradient conditions were developed with the help of the modelling. 
 
The MS/MS mode in which the fragmentation energy is increased during the MS/MS spectral 
acquisition, the so-called "SmartFrag" option, was adopted as the technique for acquiring 
MS/MS spectra. In this mode the fragmentation energy is increased in the selected range, 
either to the set upper limit or until there is no more precursor ion left in the ion trap. In this 
work the selected voltage was 1.0 V and the range was set to 30%–200% of this voltage. This 
technique was used to collect MS/MS library spectra and was used in all MS/MS methods in 
this work (I–IV) with the above-mentioned settings. 
 
4.4. AP-MALDI/MS and AP-DIOS/MS (III) 
 
A gold-coated 96-target plate was used in the MALDI experiments. For DIOS the unmodified 
porous silicon (pSi) spots were prepared by electrochemical etching as described in detail by 
Tuomikoski et al.[106] The DIOS chips were rinsed with hydrofluoric acid, stored in glass 
containers under ethanol and were allowed to dry in air before sample application.  
  
The stock solutions of amphetamines and fentanyls were prepared in MeOH (1 mg/ml) and 
the dilutions were made with deionised water and MeOH to obtain MeOH/water 1/1 (v/v) 
solutions. The MALDI matrix, α-cyano-4-hydroxycinnamic acid (α-CHCA), was used as a 
saturated solution dissolved in ACN/MeOH/0.1% trifluoroacetic acid (TFA) in water (2/1/0.1 
v/v/v). Samples of 0.4 µl were applied to the spots on the DIOS plate and samples of 0.6 µl 
(including the matrix) to the MALDI plate. The spots were allowed to dry in ambient air 
before analysis. 
 
 
  37
 
4.5. Chiral LC–UV–ESI/MS (IV) 
 
Reversed-phase (RP) and polar ionic mode (PIM) eluents were prepared daily. The pH of the 
RP eluents was adjusted with acetic acid. Whenever a new eluent system was introduced the 
columns were stabilised for 30 to 90 minutes.  
 
The chromatographic behaviour of the compounds was initially studied using stock solutions 
and UV detection (λ = 233, 258 and 285 nm). The best chromatographic separations for 
methorphan, propoxyphene and amphetamines were optimised for higher injection volume 
(20 µl) and the buffer systems were optimised for ESI/MS detection.  
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5. RESULTS AND DISCUSSION 
 
The main results of the studies are shortly described in this chapter. LC–ESI/MS/MS methods 
were developed for quick analysis of a complex mixture of analytes of differing chemical 
character and for discrimination of mass equivalent substances. High throughput tandem mass 
spectrometric screening methods relying on AP-MALDI and AP-DIOS interfaces were 
successfully applied to amphetamines and fentanyls and a direct chiral LC–MS system based 
on β-CD  was found for the chiral separation of amphetamines. For more details the reader is 
kindly asked to refer to the original publications I–IV.  
 
5.1. LC–ESI/MS/MS in fast analysis of a complex mixture (I) 
 
A seized drug unit is likely to contain numerous components: the principal drug of action 
along with various adulterants and diluents of different chemical character. To test the 
suitability of LC–ESI/MS in forensic analysis, a representative heterogeneous group of 14 
compounds was selected: acidic, basic and neutral compounds, stable and labile compounds, 
and compounds with the same nominal masses (Figure 1). The drugs included thermolabile 
compounds such as LSD, temazepam, psilocybin and buprenorphine, which, without 
derivatisation, tend to be difficult or impossible to analyse by conventional GC–MS.  
 
Positive ion mode was chosen, since with suitable mobile phase composition, it is then 
possible to ionise not only basic compounds but also neutral and acidic compounds. All the 
compounds of interest were efficiently ionised with the chosen eluent system of MeOH, water 
and 0.1% FA. All mass spectra showed an abundant [M+H]+ ion, which was selected as the 
precursor ion for MS/MS analysis. In addition, the mass spectra of the neutral compounds, i.e. 
testosterone, nandrolone and metandienone, showed relatively intense sodium adduct ion, 
[M+Na]+. A weak [M+Na]+ ion was recorded for temazepam. The mass spectra of 
salbutamol, phenobarbital, AM and 3,4-MDMA showed some fragment ions. Tandem mass 
spectrometry was chosen because the chromatography was designed to be fast, without 
complete separation of the compounds. 
 
The MS/MS spectra of all compounds showed characteristic behaviour allowing identification 
of the compounds. One characteristic and abundant product ion was chosen for quantitative 
analysis. The use of monolithic column, non-linear gradient elution and MS/MS allowed the 
analysis of all 14 compounds within five minutes, including stabilisation time before the next 
injection. Although many of the compounds were not fully separated in the LC step, as can be 
seen in Figure 2, all compounds were unambiguously identified with MS/MS. Gradient 
elution was necessary because of wide variation in the polarity of the compounds. The 
capacity factors, k, with the LC method employed were acceptable, ranging from 2.1 to 9.7 (t0 
= 0.212 min). This meant that salts and any other compounds eluting without retention were 
separated from the compounds of interest and the suppression caused by these other 
compounds in ESI was minimised. The relative standard deviation (RSD) of the retention 
times was 0.45–4.8%, indicating good reproducibility of the LC system.  
 
Suitability of the MS/MS spectra and retention times in the library for the identification of the 
compounds was tested with 476 injections of standard samples with concentrations varying 
between 0.1 and 40 µg/ml. The search algorithm compares the unknown spectrum with the 
spectra in the library (Fit) and the spectra in the library with the unknown (Rfit), and from this 
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it generates a purity value. The maximum purity value is 1000, indicating perfect correlation 
between measured and library spectra. The purity values were clearly better for concentrations 
above than below 0.3 µg/ml (640–900 above and 354–868 below). This was mainly due to 
higher background interference and lower repeatability of the relative abundances of the 
product ions at concentrations below 0.3 µg/ml. The results showed the necessity of including 
retention times to the library search, though they were less critical for the compounds 
producing several abundant product ions (morphine, buprenorphine, testosterone, stanozolol) 
than for compounds producing one very intense product ion and only a few other weak ions 
(amphetamine, 3,4-MDMA). Combining retention time and MS/MS spectral information in 
the library search improved the reliability of the identification significantly. Owing to good 
reproducibility of the LC separation, all the compounds were found within a very narrow 
retention time window (± 2.5 seconds). The library matches were also evaluated with 50 
seized samples and pharmaceutical preparations with concentrations varying from 0.2 µg/ml 
to a very high 3.75 mg/ml. The compounds, which had first been identified by conventional 
methods were all identified unambiguously by the new LC–MS/MS method with library 
search. For all samples, the correct compound was the first one in the MS/MS library hit list 
and was found within ± 3% retention time window. The retention time window was larger for 
authentic sample material because of the wider concentration range.  
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Figure 2. One point smoothed extracted ion chromatograms of the target (MRM) ions. 
Compounds are 1 Psilocybine, 2 Morphine, 3 Salbutamol, 4 Amphetamine, 5 3,4-MDMA, 6 
Clenbuterol, 7 LSD, 8 Phenobarbital, 9 Buprenorphine, 10 Temazepam, 11 Nandrolone, 12 
Metandienone 13 Testosterone, 14 Stanozolol. The concentration of each substance is 12 – 15 
µg/ml. 
 
Additionally, the suitability of the method was investigated for quantitation purposes. An 
external standard method was chosen in view of the widely varying chemical and physical 
properties of the compounds. The method was evaluated by determining linearity, 
repeatability and limits of detection (signal-to-noise ratio ≥ 3). The correlation coefficients (r) 
were between 0.993 and 0.999 within the concentration range of 0.1–30 µg/ml (n=6) 
indicating good linearity of the method. The linearity of LSD, nandrolone and buprenorphine 
began to deteriorate at concentrations above 40 µg/ml owing to saturation of the surface of the 
electrically charged droplets in ESI [183]. LODs for all compounds ranged between 10 and 50 
ng/ml, which was considered a sufficient level for this type of forensic analysis. Within-day 
reproducibility of the method was evaluated at three concentration levels (3.0, 10 and 30 
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µg/ml; five injections each). The RSDs were typically below ± 20%, but clearly higher for 
phenobarbital (± 28.8%) and AM (± 25.9%). The repeatability of the method was considered 
acceptable for purposes of forensic analysis, although it suffered from a limited number of 
data points due to co-eluting compounds and peaks that were only two to seven seconds wide. 
With the settings employed, one data point was collected in about 400 ms for one parent ion 
[i.e. accumulation time (up to 10 ms) + the scan time for m/z 50–500 (30.4 ms) + isolation 
time (290 ms) + fragmentation time (40 ms) + scan time (30.4 ms)]. If more than one 
compound is analysed within same cycle, the number of data points is decreased and may not 
be sufficient for reproducible integration of the peaks. With the ion trap employed, the time 
needed for one data point cannot be decreased from the values mentioned.  
 
5.2. LC–ESI/MS/MS in fast analysis of mass equivalent substances (II) 
 
A method relying on fast liquid chromatographic separation and tandem mass spectrometry 
was developed to distinguish the main ecstasy component 3,4-MDMA from a set of 17 mass 
equivalent isomers and isobaric substances including side chain regioisomers and different 
ring substitution patterns (Figure 1). Isobaric substances are defined as compounds of the 
same nominal mass but of different elemental composition [184]. The original hope was to 
develop a method not requiring prior LC separation, but this did not prove to be possible.  
 
The mass spectra of the 18 compounds (numbered 1–6 and 8–19, Figure 1) showed a strong 
protonated molecule at m/z 194 and one or two fragment ions. No adduct ions were seen. The 
main fragment ion depended on the length of the alkyl chain at nitrogen and was at m/z 177, 
163 or 149. As an exception, compound 19 produced a main fragment at m/z 176. The 
controlled drug 3,4-MDMA (numbered compound 3) produced m/z 194 and a fragment ion at 
m/z 163, as did compounds 8, 11, 13, 16, 17 and 18. Thus, compounds 8, 11, 13, 16, 17 and 
18 had the same main fragment ion as 3,4-MDMA.  
 
Tandem mass spectrometry (MS/MS) was applied to enhance specificity, with the strong 
protonated molecule, [M+H]+, at m/z 194 chosen as the precursor ion. The MS/MS library 
spectra were produced and the experiments carried out by increasing the fragmentation 
amplitude during the spectral acquisition. Increasing the fragmentation energy made 
comparison of the stabilities of the molecules impossible and 3,4-MDMA could only be 
distinguished from the other compounds on the basis of unique product ions or distinct 
intensity patterns.  
 
Similarly to the mass spectra the MS/MS experiments allowed a division of the compounds 
into four groups according to the main product ion appearing in the MS/MS spectra: 1) 
compounds that produced an ion at m/z 177 by the loss of ammonia, 2) compounds 3 (i.e. 3,4-
MDMA), 8, 11, 13, 16, 17 and 18 which produced an ion at m/z 163 through the loss of 
methylamine, 3) compounds that produced an ion at m/z 149 through the loss of primary 
ethylamine or secondary dimethyl amine, and 4) the keto-compound 19 that produced an ion 
at m/z 176 through the loss of water. Thus, 3,4-MDMA was distinguished from the 
compounds in groups 1, 3 and 4 according to the MS/MS spectra. Within the group 2, 3,4-
MDMA could be distinguished from compounds 16 and 17, which showed an additional 
product ion at m/z 121, most likely due to migration of the methyl group in the benzylic 
species to form the methoxybenzyl or methoxytropylium ion. 2,3-MDMA (compound 8), 
which was structurally the most similar to 3,4-MDMA, produced a product ion at m/z 135 
which was not seen for 3,4-MDMA, and thus these compounds were distinguished. When 
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3,4-MDMA was analysed with the settings used in the library search (Sect. 5.1.) but with 
direct introduction of the sample the library gave seven different hits, including all the 
compounds of group 2, which produced the same intense product ion from the same precursor 
(m/z 194  m/z 163). 
 
Misidentifications occurred because the main product ion was the only abundant ion in the 
MS/MS spectra of the compounds in group 2 and it affected the search algorithm. Hence, with 
the library settings employed, unambiguous identification of 3,4-MDMA requires 
chromatographic separation before MS/MS analysis. A fast LC separation was accordingly 
optimised to separate 3,4-MDMA from the six other compounds of group 2. The separation 
was designed so as to give the greatest possible resolution (RS) for 3,4-MDMA within a few 
minutes runtime. Figure 2 shows the LC separation of the seven compounds of group 2 in 
black. The other 11 compounds studied are shown in grey.  
 
Figure 3. LC separation of the 18 compounds with equivalent mass, including 3,4-MDMA. 
The chromatogram for transition m/z 194m/z 163 for the seven compounds in group 2 is 
shown in black and the other transitions in grey. The peak of 3,4-MDMA is marked with 
number 3. The concentrations of the compounds were 10 or 20 µg/ml. 
 
Although not all of the substances could be identified, application of the developed LC–
ESI/MS/MS method and automated library search allowed confirmation of the presence of 
3,4-MDMA in the presence of 17 of its mass equivalent substances. From 11 of the 
compounds it was quickly distinguished by MS/MS with library search. From the six 
interfering compounds with similar fragmentation pattern, 3,4-MDMA (tR = 1.51 min) was 
separated within a five minute LC run. Compound 19 co-eluted with 3,4-MDMA, and co-
elution can cause a mixture spectrum. However, compound 19 was easily recognised as the 
only compound that produced unique product ions with intensive fragment ion at m/z 176. 
 
5.3. High-throughput screening by AP-MALDI/MS/MS and AP-DIOS/MS/MS (III) 
 
With the continuing demand of analytical laboratories for new, fast and cost effective 
techniques, a preliminary study was carried out on the applicability of new atmospheric 
pressure desorption ionisation techniques in detection and identification of illicit drugs. The 
new techniques matrix assisted laser desorption ionisation (MALDI) and desorption ionisation 
on silicon (DIOS) at atmospheric pressure were investigated with MS/MS. MALDI and DIOS 
techniques are attractive to analytical laboratories requiring high sample throughput, because 
analyses are extremely fast and are easily automated. In view of their current importance, the 
investigation was carried out with amphetamine derivatives and fentanyls as model 
compounds.  
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The AP-MALDI/MS and AP-DIOS/MS parameters were optimised to maximise the absolute 
abundance of the protonated molecule. The effect of temperature of the drying gas in the ion 
source was tested between 45 and 150°C, and the maximal absolute abundance of the 
protonated molecule was found at 45°C. Although MDA, PMA and NE fragmented strongly 
even at this low temperature, the protonated molecule was still abundant. Increase of the 
temperature to 100°C increased fragmentation but still had no significant effect on the 
absolute abundances of the protonated molecules. The fragmentation increased further when 
the temperature was raised to 150 °C. High temperatures in the AP-MALDI ion source or ion 
optics have been applied in peptide analyses to prevent analyte–matrix cluster ion formation 
[27,185]. AP-MALDI spectra of the test compounds measured at 45 °C did not show any 
cluster ions, however, and the same conditions were used for both MALDI and DIOS 
techniques. Under these optimised conditions and with the plate operated in fixed position, 
the signal of the protonated molecule of 3-MF (18 pmol) lasted for about 10 minutes in DIOS 
experiments and about 5 minutes in MALDI experiments. The plate can also be moved 
spirally during the laser pulses. In spiral mode the signal lasted over 30 minutes in DIOS 
experiments and over 20 minutes in MALDI experiments. Such a long-lasting signal allows 
sequential analysis, such as is needed in optimisation of laser pulse energy and in MS and 
MSn analysis from a single spot.  
 
All mass spectra of the compounds exhibited abundant protonated molecules. With AP-DIOS 
the background disturbances were minimal. Although the relative abundances of the matrix 
background ions (e.g. m/z 379, 172, 144) were clearly higher with AP-MALDI, they still did 
not interfere with the analyses. The α-CHCA matrix is known to interfere with analyses of 
some low molecular mass compounds [186]. All the compounds studied have high proton 
affinity and their ionisation efficiency in DIOS and MALDI was very good, therefore. The 
high ionisation efficiency of such compounds was in good agreement with earlier studies 
[122]. The fragmentation was minimal for all amphetamine derivatives except MDA, PMA 
and NE, which showed a few intense fragment ions. Likewise, among the fentanyls, 3-MF, α-
methylfentanyl, sufentanil, alfentanil, and β-hydroxyfentanyl showed little dissociation with 
DIOS/MS. 
 
Mixtures of all nine amphetamine derivatives were analysed by AP-MALDI/MS/MS and AP-
DIOS/MS/MS to determine the applicability of the techniques in detection and identification 
of a single analyte in a sample containing several compounds of the same type. The 
protonated molecules of the compounds (Figure 4) were isolated automatically in sequence 
and fragmented by MS/MS during one run from one spot. The MS/MS spectra obtained with 
AP-MALDI and AP-DIOS (Figure 5) were compared against an in-house reference ESI–
MS/MS spectral library created earlier with use of the same type of mass spectrometer and 
similar fragmentation conditions.  
 
The AP-MALDI/MS/MS and AP-DIOS/MS/MS spectra of the amphetamine derivatives are 
presented in Figure 5. The MS/MS fragmentation of the protonated molecule was similar to 
that produced by ESI (IV). The AP-MALDI/MS/MS and AP-DIOS/MS/MS spectra showed 
the same intense product ion due to the alkylamine loss as was described for 3,4-MDMA 
isomers in Sect. 5.2. Fentanyls fragmented in MS/MS experiments mainly through neutral 
loss of the amide moiety (route A) and neutral loss of the amine moiety (route B). The third 
important fragmentation route was the cleavage of the piperidine ring and loss of the 
propionyl group (route C) (Figure 3 in III). The fentanyls including a hydroxy group, i.e. β-
hydroxyfentanyl and β-hydroxy-3-methylfentanyl, produced abundant product ions upon loss 
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of water, m/z 335 and m/z 349, respectively. Sufentanil produced abundant product ion with 
m/z 355 upon loss of sulphur.  
 
 
 
 
Figure 4. (A) AP-DIOS and (B) AP-MALDI mass spectra for a mixture of amphetamine 
derivatives: AM (m/z 136), MA (m/z 150), PMA (m/z 166), PCA (m/z 170), PMMA (m/z 
180), MDA (m/z 180), MDMA (m/z 194), MDEA (m/z 208)(120 pmol) and NE (m/z 
152)(290 pmol) 
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Figure 5. MS/MS spectra measured by AP-DIOS (A) and AP-MALDI (B), for a mixture of 
amphetamine derivatives: AM, MA, PMA, PCA, PMMA, MDA, MDMA, MDEA 
concentrations of 120 pmol and NE concentration of 290 pmol. The diamonds indicate the 
precursor ion. 
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All MS/MS spectra measured in this work corresponded well with the library spectra obtained 
by ESI under similar conditions. Although PMMA and MDA have a common precursor ion 
(m/z 180), they could be identified unambiguously by means of their specific product ions, 
m/z 163 for MDA and m/z 149 for PMMA. The difference in the intensities of the product 
ions (Figure 5) is evidently due to the dissociation of MDA in the ion source, which also 
contributed to its higher LOD. The MS/MS spectra of fentanyls showed more diagnostic and 
specific product ions than those of amphetamine derivatives, and also all fentanyls studied 
were identified unambiguously. Even 3-MF and α-methylfentanyl, which have a common 
precursor ion (m/z 351), were distinguished by MS/MS, as they produced different and 
specific product ions: 3-MF produced m/z 230 and α-methylfentanyl m/z 216, both by route 
B. Where compounds have the same precursor and the same product ions, as some of the 
compounds in study II, these techniques cannot provide sufficient selectivity. 
 
The LODs (signal-to-noise ratio 10) for amphetamine derivatives and fentanyls measured by 
AP-DIOS/MS/MS were between 100 and 1000 ng/ml (1 and 3 pmol) indicating excellent 
sensitivity of the technique. The good ionisation efficiency is due to high proton affinity of 
the amino groups of the compounds. The same was recognised in earlier work where 
propranolol was investigated by AP-DIOS [122]. For MA, 3,4-MDMA and 3-MF, the LODs 
were also measured by AP-MALDI, and they were five to ten times higher than with DIOS 
indicating better sensitivity of AP-DIOS. The quantitative repeatability of AP-DIOS/MS/MS 
was only tentatively investigated by measuring the absolute abundance of the main product 
ion of 3-MF (m/z 351  m/z 202). The relative standard deviation (RSD) from five (3+2) 
sample spots (110 pmol) on two DIOS chips was relatively good at 16%. This level of 
repeatability is quite sufficient for qualitative forensic target analyte screening. 
 
Also seized samples of fentanyls and amphetamines were analysed to assess the suitability of 
the techniques for the analysis of real forensic samples. An example of an analysis of an 
ecstasy tablet is shown in Figure 6. The AP-MALDI/MS and AP-DIOS/MS spectra of the 
tablet were clean and showed a signal at m/z 194 and no signals from other active substances. 
The matrix constituents in the tablet did not disturb the analyses, nor did the α-CHCA matrix 
in AP-MALDI. The MS/MS spectrum showed an abundant ion at m/z 163 and a minor ion at 
m/z 58, and the compound was identified by library search as 3,4-MDMA.  
 
 
 
Figure 6. AP-DIOS/MS (A), AP-DIOS/MS/MS (B), AP-MALDI/MS (C) and AP-
MALDI/MS/MS (D) spectra of a powder sample containing 3,4-MDMA, and MS/MS library 
spectrum of 3,4-MDMA (E). 
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which means that with the sample preparation technique employed (only 1 mg was weighed) 
the lowest detectable amount of the analyte in drug seizure samples is between 0.5 and 5 
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to 600 µg/mg, that is more than 80 times higher than the limit of detection. This and the 
analysis of the seized samples clearly show that AP-DIOS/MS/MS is suitable for the analysis 
of amphetamines and fentanyls present in seized samples at low concentrations.  
 
5.4. Effect of eluent in direct chiral LC separation of amphetamine derivatives (IV) 
 
Because some compounds are controlled only as one optical isomer, determining the licit or 
illicit nature of a sample sometimes depends on chiral separation. Within the EU, however, all 
of the studied amphetamine derivatives and their enantiomers are controlled drugs, except NE 
which is controlled only as a precursor for preparing illicit drugs [187].  
 
Methorphan, propoxyphene and MA were used as model compounds in a comparison of 46 
eluent compositions tested in the development of chiral LC–MS methods. Vancomycin, a 
novel chiral stationary phase for these compounds and the more commonly used β-CD were 
evaluated as chiral stationary phases (CSP). Both can be used in normal-phase, reversed-
phase or polar organic phase modes. Because only polar eluent systems with high enough 
conductivity are suitable for ESI, nonpolar eluent systems were not tested.  
 
Only the enantiomer separation of amphetamine derivatives is discussed here; the results for 
methorphan and propoxyphene can be found in the original manuscript (IV). Development of 
a method for chiral separation is a time-consuming and highly empirical process because it is 
difficult to predict the selectivity of analytes on commercial CSPs. The results for MA were 
used in choosing suitable conditions for the eight other amines, but it was kept in mind that 
closely related molecules do not necessarily behave similarly in chiral separation systems. 
The eluent systems investigated are presented in Table 6. 
 
5.4.1. Reversed-phase and polar ionic modes with vancomycin column 
 
The effect of the eluents 1–14 (Table 6) on the resolution and retention of enantiomers of MA 
was studied in the reversed phase (RP) mode with the vancomycin column. The results 
indicated that MeOH and i-PrOH provide enantiomer separation, while ACN does not. The 
result for ACN was confirmed by running all the amphetamine derivatives with 70/30 
ACN/0.1% TEAA. As with MA, none of the enantiomers of the amphetamine derivatives 
were separated. Plots showing the effect of the amount of organic modifier on retention were 
U-shaped as is typical for glycopeptide columns (Figure 7)[54]. 
 
The best enantiomer separation for MA was obtained with the eluents 9, 10 and 14. However, 
owing to the more nonpolar character of i-PrOH (14) than of MeOH, the retention times were 
significantly longer than those with the eluents 9 and 10, and also the backpressure was 
higher. The best enantiomer separation for MA with a reasonable retention factor (k = 2.1) 
was achieved with eluent 9 (80% MeOH), and this was chosen for further studies. Eluent 9 
also showed acceptable resolution for all the other amphetamines, except for the enantiomers 
of PCA, MDEA and NE. The latter two compounds were not enantiomer separated on the 
vancomycin column with any solvent composition. The best separation for PCA was obtained 
with eluent 6 (Rs = 0.6). The resolution and retention factors for the amphetamines with all 
eluent systems are presented in Figure 7. 
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Table 6 The eluent systems investigated in reversed-phase (RP) and polar ionic modes (PIM) 
with vancomycin and β-CD columns. 
 
No. Vancomycin (RP) No. β-CD (RP) 
1 ACN/0.1% TEAA 30/70, pH 4 23 ACN/1.0% TEAA 5/95, pH 4 
2 ACN/0.1% TEAA 50/50, pH 4 24 ACN/1.0% TEAA 10/90, pH 4 
3 ACN/0.1% TEAA 70/30, pH 4 25 ACN/1.0% TEAA 15/85, pH 4 
4 ACN/0.1% TEAA 90/10, pH 4 26 MeOH/1.0% TEAA 5/95, pH 4 
5 MeOH/0.1% TEAA 30/70, pH 4 27 MeOH/1.0% TEAA 10/90, pH 4 
6 MeOH/0.1% TEAA 40/60, pH 4 28 MeOH/1.0% TEAA 15/85, pH 4 
7 MeOH/0.1% TEAA 50/50, pH 4 29 i-PrOH/1.0% TEAA 5/95, pH 4 
8 MeOH/0.1% TEAA 70/30, pH 4 30 i-PrOH/1.0% TEAA 10/90, pH 4 
9 MeOH/0.1% TEAA 80/20, pH 4 (5, 6, 7) 31 i-PrOH/1.0% TEAA 15/85, pH 4 
10 MeOH/0.1% TEAA 90/10, pH 4 32 ACN/100 mM NH4OAc 5/95, pH 4 
11 i-PrOH/0.1% TEAA 30/70, pH 4 33 MeOH/100 mM NH4OAc 5/95, pH 4 
12 i-PrOH/0.1% TEAA 50/50, pH 4 34 MeOH/100 mM NH4OAc 15/85, pH 4 
13 i-PrOH/0.1% TEAA 70/30, pH 4   
14 i-PrOH/0.1% TEAA 90/10, pH 4   
No. Vancomycin (PIM) No. β-CD (PIM) 
15 MeOH/ACN/HOAc/TEA 70/30/0.03/0.02 35 MeOH/ACN/HOAc/TEA 10/90/0.03/0.02
16 MeOH/ACN/HOAc/TEA 70/30/0.03/0.04 36 MeOH/ACN/HOAc/TEA 15/85/0.03/0.02
17 MeOH/ACN/HOAc/TEA 70/30/0.06/0.02 37 MeOH/ACN/HOAc/TEA 20/80/0.03/0.02
18 MeOH/ACN/HOAc/TEA 70/30/0.5/0.05 38 MeOH/ACN/HOAc/TEA 25/75/0.03/0.02
19 MeOH/ACN/HOAc/TEA 70/30/0.6/0.2 39 MeOH/ACN/HOAc/TEA 30/70/0.03/0.02
20 MeOH/ACN/HOAc/TEA 70/30/0.9/0.1 40 MeOH/ACN/HOAc/TEA 15/85/0.3/0.2 
21 MeOH/HOAc/TEA 100/0.03/0.02 41 MeOH/ACN/HOAc/TEA 15/85/0.3/0.4 
22 MeOH/HOAc/TEA 100/0.06/0.02 42 MeOH/ACN/HOAc/TEA 15/85/0.6/0.2 
 43 MeOH/ACN/HOAc/TEA 15/85/0.9/01 
 
 
The mode in which acid and base are used to adjust the ionisation state of the chiral selector 
has recently been designated the polar ionic mode (PIM) to distinguish it from polar organic 
phase (POP) mode where no acid or base is added to the organic eluent [188]. We use the new 
term here, though the old term was used in the original manuscript (IV). The polar ionic mode 
(PIM) was tested using the vancomycin column and eight different mobile phase 
compositions (eluents 15–22, Table 6). The initial mobile phase (eluent 15) was selected on 
the basis of an earlier study of clenbuterol [189] and this was modified by varying the 
acid/base ratio, and finally the MeOH/ACN ratio. In PIM, the acid/base ratio and the 
concentrations of acid and base are the most important parameters in controlling resolution 
and retention, respectively.  
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Figure 7. Retention factors and resolution of the amphetamine derivatives with the tested 
eluent systems. For explanation of the eluent systems, see Table 6. Systems 1–22 were run 
with vancomycin CSP and systems 23–43 with β-CD CSP. Eluent systems marked with an 
asterisk were not run. 
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eluent 21. As can be seen, the resolution of the enantiomers of MA was decreased with an 
addition of acetonitrile (eluents 15–20) indicating the importance of hydrogen bonding 
capability of the hydroxyl group of MeOH.  
 
The results obtained with MA were confirmed by running all the amphetamine derivatives 
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instead of MeOH/ACN mixture was evident particularly for MDMA, MDA and PMA, which 
were not enantiomer separated with any of the eluents containing ACN but were resolved 
with 100% MeOH (eluents 21 and 22). An exception to other amphetamines was PCA which 
showed better separation with an increased amount of ACN (Figure 7).  
 
5.4.2. Reversed-phase and polar ionic modes with β-cyclodextrin column 
 
Use of the RP eluents 23–34 with the β-CD column provided an acceptable separation for 
MA. As in the earlier studies [84], it was clear that the amount of the organic modifier must 
be low (<15%) and the buffer concentration relatively high (1% TEAA) in order to achieve an 
acceptable resolution for amphetamine derivatives. The retention increased together with the 
resolution when the polarity of the solvent system was increased. The order of the elution 
strength of the organic modifier was i-PrOH > ACN > MeOH (Figure 7) indicating that the 
β-CD column, unlike vancomycin, behaves as an RP column.  
 
The best results for MA were obtained with MeOH as organic modifier (eluents 26, 27 and 
28). The best resolution with reasonable retention was achieved with eluent 26, which also 
provided acceptable resolution for all the other amphetamine derivatives except NE (Figure 
7). Furthermore, this eluent enabled a chromatographic separation of the amphetamines and 
their enantiomers from each other allowing their analysis as a mixture by UV detection. The 
amphetamine derivatives eluted from the β-CD column in increasing order of size. Likewise, 
in an earlier study, with β-CD as a background electrolyte in CE, the migration order 
corresponded with increasing molecular mass (MDA<MDMA<MDEA) [73]. Sadeghipour et 
al. [87] and Brunnenberg and Kovar [47] reported that with RP mode and native β-CD, the 
R(–)-enantiomer always eluted before S(+). This was evidently also true in our experiments 
with β-CD.  
 
Since MA showed no enantiomer separation on the β-CD column in PIM (Figure 7), the 
other amphetamine derivatives were not run in this mode. 
 
5.4.3. Effect of molecular structure on resolution and comparison of methods 
 
The effect of length of an alkyl chain near the chiral centre of the amphetamine derivatives on 
the enantiomer separation was studied by comparing MDA, MDMA and MDEA with each 
other, PMA and PMMA with each other and AM and MA with each other (Figure 7). The 
comparison with the vancomycin column in RP and PIM showed that, with two exceptions 
the enantiomer resolution decreases as the length of the alkyl chain increases and the ethyl 
substituent (MDEA) prevents the chiral separation totally. The reason may be that a longer 
alkyl chain causes increased steric hindrance for interaction between the amino groups of 
amphetamines and the acidic groups of vancomycin. The exceptions were MDMA and MDA 
in PIM. The effect of the alkyl chain length was not significant in enantiomer separation with 
β-CD. However, the size of the molecule had a significant effect on the retention, as the 
amphetamines eluted from the β-CD column in increasing order of size.  
 
The effect of the electrophilic substituents in the aromatic ring of the amphetamine derivatives 
was studied by comparing AM, PMA, MDA and PCA with each other and MA, PMMA and 
MDMA with each other. With the vancomycin column in RP and PIM, the enantiomer 
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separation of the amphetamine derivatives was clearly influenced by the electrophilic 
substituents at the aromatic ring. The compounds without substituents (AM, MA) showed best 
resolution, but the methoxy compounds (PMA, PMMA) showed almost as good resolution. 
The dimethoxy substitution in MDA and MDMA decreased the resolution significantly, and 
chlorine totally prevented the separation of enantiomers of PCA with eluent 9 in the 
vancomycin column. These results suggest that π-π interactions between the aromatic ring of 
the amphetamines and vancomycin have an effect on the resolution. With β-CD column, the 
electrophilicity of the substituents in the phenyl ring affected the resolution only a little. 
Interestingly, NE, which has a hydroxyl group at the carbon adjacent to the chiral centre, did 
not show enantiomer separation with any of the methods tested.  
 
The best single method for at least partial separation of most of the amphetamine derivatives 
was based on the β-CD column with RP eluent 26 (MeOH/1.0% TEAA 5/95). All 
amphetamine derivatives were separated except NE. The β-CD column with RP eluent 26 was 
also able to separate the amphetamines from each other far better than the vancomycin 
column with any eluent. However, the vancomycin column provided better enantiomer 
separation for AM, PMMA, and PMA as individual compounds (Figure 7).  
 
5.4.4. Chiral LC–ESI/MS 
 
After determination of the β-CD column with eluent system 26 as the best combination for the 
separation of enantiomers of amphetamine derivatives in a mixture, the suitability of this 
system was tested in LC–ESI/MS/MS detection. The method was not directly suitable since 
the high TEAA concentration (1%) caused severe suppression of ionisation and led to lower 
sensitivity and rapid contamination of the ion source. Therefore, 1% TEAA (72 mM) was 
replaced by 100 mM ammonium acetate (eluent 33), which showed comparable resolution 
with somewhat increased retention (Figure 7). Sensitivity was better with ammonium acetate 
than with TEAA due to decreased suppression. Figure 8 shows extracted product ion 
chromatograms for enantiomers of amphetamine derivative.  
 
 
 
Figure 8. Extracted product ion chromatograms of eight amphetamine derivatives. Method: 
MeOH/100 mM NH4OAc 5/95 (eluent 33) and β-CD column. Compounds: 1 R-AM, 2 S-AM, 
3 R-MA, 4 S-MA, 5 R-PMA, 6 S-PMA, 7 R-PCA, 8 S-PCA, 9 R-PMMA, 10 S-PMMA, 11 
R-MDA, 12 S-MDA, 13 R-MDMA, 14 S-MDMA, 15 R-MDEA, 16 S-MDEA. Sample 
concentrations 35 – 130 µg/ml. 
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The LC–ESI/MS/MS method was evaluated by determining the LODs, repeatability of the 
peak areas of the product ion chromatograms and retention times. Since identification of the 
compounds was all that was intended a complete quantitative evaluation was not performed. 
The relative standard deviations of the peak areas were between 2.4 and 11.4% and those of 
the retention times between 0.2 and 1.3%. The repeatability of the method was thus 
acceptable. The LODs were between 25 and 1000 ng/ml, which can be considered acceptable 
for forensic analysis.  
 
Figure 9 shows an analysis of amphetamine derivatives from an ecstasy tablet by LC–UV–
ESI/MS/MS using the β-CD column and the RP eluent 33. The extracted product ion 
chromatograms show that the sample included a high concentration of MDMA, with MDA 
and amphetamine as impurities. The high concentration of MDMA overloaded the column 
causing peak tailing and a shift in the retention times. A more dilute sample had to be injected 
separately to get reasonable peak shapes for AM and MDMA and a more concentrated sample 
to detect MDA. 
 
 
 
Figure 9. An ecstasy tablet analysed on β-CD column with eluent 33 (see Table 6). Extracted 
product ion chromatograms of 1 and 2 AM, 3 and 4 MDMA and their corresponding UV 
trace. The lowest trace is from a second injection of a more concentrated sample, 5 and 6 
MDA. 
EIC 136->119 
3      4 EIC 194 ->163 
1 2 
3 4 UV 258 nm 
0.5 
1.0 
x10 4 
0 
1 
2 
x10 5 
0 
1 
mAU 
15 25 35 40
5 6
EIC 180 ->163 
0 
2 
4 
6 
x10 4 
0 5 10 20 30 Time (min) 
Intensity 
1 2 
Intensity 
Intensity 
  53
6. CONCLUSIONS 
 
The fast LC–ESI/MS/MS methods developed in this work were shown to be applicable for 
detection, confirmation and quantitation of a variety of forensically interesting compounds. 
The results showed that chemically very different compounds – basic, acidic and neutral – can 
be ionised by positive ion ESI and quantitatively analysed in one run. All 14 compounds were 
quantitatively analysed on monolithic analytical column within 2.5 minutes. Moreover, the 
technique proved suitable for analysing compounds that are not easily analysed by 
conventional GC–MS. It was also shown that the method can be used in distinguishing a 
controlled drug from chemically closely similar compounds, i.e. from mass equivalent 
regioisomers and isobaric substances. A controlled drug was distinguished within five 
minutes from 17 similar compounds generating the same precursor ion. It was clear, however, 
that selective and fast LC of any mixture is appropriate only with tandem mass spectrometers. 
The quadrupole ion trap (QIT) mass spectrometer was used throughout the study. 
 
In-house libraries including MS and MS/MS spectra and also the retention times of the 
compounds of interest provided fast identification. Comprising LC separation, tandem mass 
spectrometry and spectral comparison against in-house libraries, the methods developed were 
highly specific and reliable. Automated library search was considered essential because of the 
vast amounts of data generated in faster analyses with a specific detector with fast acquisition 
rate. With automated library search, the data handling process is kept simple even for the less 
experienced user. The speed, specificity, ruggedness and possibility to automate the data 
analysis make the new methods highly attractive for forensic routines.  
 
Preliminary studies on the use of AP-MALDI/MS/MS and AP-DIOS/MS/MS for detection 
and identification of drugs of abuse confirmed that both techniques are suitable for very fast 
screening of selected amphetamine derivatives and fentanyls in samples obtained in drug 
seizures. In neither technique did the background ions disturb the analysis, since in both cases 
these appeared at higher or different mass numbers than the analytes. The LODs demonstrated 
high sensitivity for both techniques, suggesting their potential in trace analysis as well. In 
future, the work could be automated to allow the analysis of up to 100 samples on a single 
MALDI or DIOS plate. After initial investment, both techniques should also be highly cost 
effective. For all these reasons, AP-MALDI/MS/MS and AP-DIOS/MS/MS are of great 
interest for forensic purposes. An important finding was that the MS/MS spectra of the 
compounds studied were similar regardless of the ionisation technique: AP-MALDI, AP-
DIOS or ESI. Thus, library spectra to be used in identifications could be generated with any 
of these techniques. The spectra must be generated under the same conditions, however, and 
with the same type of MS instrument.  
 
The study on eluent composition in chiral separations provided information on the chiral 
separation mechanisms. Evaluation of a selection of reversed-phase and polar ionic mode 
eluent systems compatible with ESI/MS showed that even small changes in eluent 
composition may affect the resolution significantly. Although very similar molecules can act 
very differently in chiral systems some predictions of the chiral separation of amphetamine 
derivatives could be made on the basis of analyses conducted with methamphetamine. Several 
amphetamine derivatives was separated within a single run, a feature that would be beneficial 
when determining the chiral composition of drug seizures containing several amphetamine 
derivatives or in successive analyses of different amphetamine samples. 
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The β-CD column with reversed-phase eluent system was more suitable for chiral analysis of 
amphetamine derivatives in general than the vancomycin column. The β-CD column not only 
allowed the separation of enantiomers of the amphetamine derivatives, but also nearly 
baseline separation of the derivatives from each other. Non-volatile TEAA, which caused 
severe signal suppression in ESI/MS, could be replaced by ammonium acetate without 
reduction of the resolution. Evidently vancomycin has not previously been used as a chiral 
selector for amphetamine derivatives, methorphan or propoxyphene. The performance of 
vancomycin as a chiral selector was only reasonable. However, when comparison was made 
of the β-CD column and vancomycin with the several eluent systems tested the vancomycin 
selector was more enantiomer selective for amphetamine, p-methoxyamphetamine, p-
methoxymethamphetamine, methorphan and propoxyphene. In future, this selector could 
provide valuable applications for these analytes. Neither of the chiral selectors could separate 
the enantiomers of norephedrine. Furthermore, since eluent splitting was used in this work, 
and the LODs were sufficient for forensic contexts, it is clear that chiral LC–MS will benefit 
in future when smaller diameter chiral columns become widely available.  
 
Even though the suitability of the new methods was also tested with sample material seized 
by local authorities, more work is needed before AP-MALDI/MS/MS and AP-DIOS/MS/MS 
methods can be considered reliable tools for routine forensic casework. Given the importance 
of reliability in forensic casework, expert knowledge of the operational parameters affecting 
the performance of sophisticated mass spectrometric techniques will be critical both in the 
introduction of new techniques and in developing and maintaining new methods for forensic 
purposes. 
 
 
 
 
  55
ACKNOWLEDGEMENTS 
 
The experimental work for this study was carried out in the years 2002–2004 at the Crime 
Laboratory of the National Bureau of Investigation; at the Division of Pharmaceutical 
Chemistry, University of Helsinki; and at the Protein Chemistry Unit, Biomedicum Helsinki, 
University of Helsinki. Financial support was provided by the Jenny and Antti Wihuri 
Foundation and the Finnish Konkordia Society. 
 
I am most grateful to my enthusiastic and realistic supervisor, Professor Risto Kostiainen, for 
guiding and inspiring me throughout this investigation and for sharing his expertise in mass 
spectrometry. Without his support, this work would never have been completed. 
 
I wish to thank Professor Kimmo Himberg, the head of the Crime Laboratory, and Teppo 
Talka, the head of the Chemistry Department of the Crime Laboratory, for putting the 
facilities of the Laboratory at my disposal. I am further grateful to Docent Marc Baumann for 
giving me access to the AP–MALDI/ion trap of the Protein Chemistry Unit at Biomedicum. 
 
My co-authors and the two reviewers of the thesis, Professor Kimmo Peltonen and Docent 
Ilkka Ojanperä, offered valuable comments on the manuscripts. Dr. Kathleen Ahonen 
improved the language of the thesis and publication III, while Heli Roppola assisted with 
publications I, II and IV. 
 
I am indebted to Ulla-Maija, Laura, Tuula, Elisa, Marianne, Liisa, Hillevi, Minna, Teppo and 
all of you behind the scenes at the Crime Laboratory for your friendship, support, assistance 
and company, in good times as well as more difficult ones. 
 
To my dear friends, especially Rouvat, Liukumiinat and Minnis, many thanks for the 
therapeutical extracurricular activities and advice you arranged in my pursuit of personal 
development. My parents Maija-Liisa and Esko and my sister Hanne and her family are 
warmly thanked for their unconditional support even when my quest for scientific 
understanding took the most absurd turns. Thanks go as well to Klaus’ family for their 
support.  
 
My deepest debt of gratitude, however, is owed to Klaus, my best friend and beloved 
companion, for his inspiration, belief and love, and not least for being tireless in making me 
the most exquisite meals. Please do not stop, ever.  
 
And last, thanks Maija—our beautiful little daughter, who came into our lives in the midst of 
all this and made everything more interesting and joyful.  
 
Thank you all. 
  56 
REFERENCES  
 
[1]  United Nations, Single convention on narcotic drugs 1961, Convention on 
psychotropic substances 1971 and Convention against the illicit traffic in narcotic 
drugs and psychotropic substances 1988; the schedules and their later amendments. 
http://www.incb.org/e/conv/1961/index.htm, http://www.incb.org/e/conv/1971/index.htm 
and http://www.incb.org/e/conv/1988/index.htm (Accessed April 12 2005). 
[2]  T.A. Brettell, K. Inman, N. Rudin, R. Saferstein, Forensic Science, Applications review, 
Anal. Chem. 71 (1999) 235R–255R. (782 references) 
[3]  T.A. Brettell, K. Inman, N. Rudin, R. Saferstein, Forensic Science, Applications review, 
Anal. Chem. 73 (2001) 2735–2744. (243 references) 
[4]  H.H. Maurer, in: Mass spectral and GC data of drugs, poisons, pesticides, pollutants and 
their metabolites, Part 1, 2nd ed. Ed. K. Pfleger, H.H. Maurer, A. Weber, Wiley-VCH, 
Weinheim, Germany, 1992, p. 3–4. 
[5]  Society of Forensic Toxicology, Inc. and American Academy of Forensic Sciences,  
 Toxicology Section, Forensic Toxicology Laboratory Guidelines. 2002, USA, 1-23.  
 http://www.soft-tox.org/docs/Guidelines.2002.final.pdf (Accessed April 12 2005)  
[6]  International Standard for Laboratories, Version 4, World Anti-doping Agency, August, 
2004 and its Technical Document TD2003IDCR. http://www.wada-ama.org (Accessed April 
12 2003) 
[7]   http://www.enfsi.org (Accessed April 12 2005) 
[8]   SWGDRUG working group, Report of the Fall 2003 SWGDRUG conference. 
http://www.swgdrug.org (Accessed March 23 2004).  
[9]   G. Bringmann, K. Messer, M. Wohlfarth, J. Kraus, K. Dumbuya, M. Rueckert, LC–CD on-
line coupling in combination with LC–NMR and LC–MS/MS for the determination of the 
full absolute stereostructure of new metabolites in plant extracts. Anal. Chem., 71 (1999) 
2678–2686. 
[10]   J.-L. Wolfender, K. Ndjoko, K. Hostettmann, The potential of LC–NMR in phytochemical 
analysis. Phytochem. Anal., 12 (2001) 2–22. 
[11]   I.S. Lurie, Capillary electrophoresis of illicit drug seizures. Forensic Sci. Int., 92 (1998) 
125–136. 
[12]   R.E. Ardey, Mass Spectrometry, In: Clarke's isolation and identification of drugs, 2nd ed., 
Ed. A.C. Moffat, J.V. Jackson, M.S. Moss, B. Widdop, The Pharmaceutical Press, London 
England, 1986, p. 251–263. 
[13]  M. Gloger, Ch. 3 Forensic analysis of drugs and technical products by gas chromatography 
and mass spectrometry. In: Analytical methods in forensic chemistry, 1st ed. Ed. M.H.Ho, 
Ellis Horwood Ltd., Chichester, England, 1990, p. 29–39. 
[14]   A. Polettini, A. Groppi, C. Vignali, M. Montagna, Fully-automated systematic toxicological 
analysis of drugs, poisons and metabolites in whole blood, urine, and plasma by gas 
chromatography-full scan mass spectrometry. J. Chromatogr. B, 713 (1998) 265–279. 
[15]  J.F. Van Bocxlaer, K.M. Clauwaert, W.E. Lambert, D.L. Deforce, E.G. Van den Eeckhout, 
A.P. De Leenheer, LC–MS in forensic toxicology. Mass Spectrom. Rev., 19 (2000) 165–
214.  
[16]   L. Rivier, Criteria for the identification of compounds by LC–MS and LC–multiple mass 
spectrometry in forensic toxicology and doping analyses, review. Anal. Chim. Acta, 492 
(2003) 69–82. 
[17]   European Union decision 2002/657/EC 17.8.2002, Off. J. Eur. Commun., 221 (2002) 8–36. 
[18]   O.H. Drummer, Chromatographic screening techniques in systematic toxicological analysis. 
A review. J. Chromatogr. B, 733 (1999) 27–45. 
[19]   W. Weinmann, A. Wiedemann, B. Eppinger, M. Renz, M. Svoboda, Screening for drugs in 
serum by electrospray ionization/collision-induced dissociation and library searching. J. 
Am. Soc. Mass Spectrom., 10 (1999) 1028–1037. 
  57
[20]   W. Weinmann, N. Lehmann, M. Renz, A. Wiedemann, M. Svoboda, Screening for drugs in 
serum and urine by LC/ESI/CID-MS and MS/MS with library searching. Z Zagadnien Nauk 
Sadowych, 42 (2000) 202–208. 
[21]   M.W.F. Nielen, J.P.C. Vissers, R.E.M. Fuchs, J.W. van Velde, A. Lomme, Screening for 
anabolic steroids and related compounds in illegal cocktails by LC–TOF/MS and LC–
QTOF/MS with accurate mass measurement. Rapid Commun. Mass Spectrom., 15 (2001) 
1577–1585. 
[22]   W.M.A. Niessen, Progress in LC–MS instrumentation and its impact on high-throughput 
screening, J. Chromatogr. A, 1000 (2003) 413–436. 
[23]   P. Marquet, N. Venisse, E. Lacassie, G. Lachâtre, In-source CID mass spectral libraries for 
the "general unknown" screening of drugs and toxicants. Analusis, 28 (2000) 925–934. 
[24]   P. Marquet, Is LC–MS suitable for a comprehensive screening of drugs and poisons in 
clinical toxicology? Ther. Drug Monit., 24 (2002) 125–133. 
[25]   F. Saint-Marcoux, G. Lachâtre, P. Marquet, Evaluation of an improved general unknown 
screening procedure using LC–ESI/MS by comparison with GC and LC–DAD. J. Am. Soc. 
Mass Spectrom., 14 (2003) 14–22. 
[26]   P. Marquet, F. Saint-Marcoux, T.N. Gamble, J.C.Y. Leblanc, Comparison of a preliminary 
procedure for the general unknown screening of drugs and toxic compounds using a 
quadrupole-linear ion-trap mass spectrometer with a LC–MS reference technique. J. 
Chromatogr. B, 789 (2003) 9–18. 
[27]   N. Venisse, P. Marquet, E. Duchoslav, J.L. Dupuy, G. Lachâtre, A general unknown 
screening procedure for drugs and toxic compounds in serum using LC–ESI/single 
quadrupole MS. J. Anal Toxicol., 27 (2003) 7–14. 
[28]   M. Gergov, I. Ojanperä, E. Vuori, Simultaneous screening for 238 drugs in blood by LC–
ionspray/MS/MS with multiple-reaction monitoring. J. Chromatogr. B, 795 (2003) 41–53. 
[29]   A. Pelander, I. Ojanperä, S. Laks, I. Rasanen, E. Vuori, Toxicological screening with 
formula-based metabolite identification by LC–time-of-flight MS. Anal. Chem., 75 (2003) 
5710–5718. 
[30]   The role of the quantity in the prosecution of drug offences. ELDD Comparative Study 
EMCDDA April 2003 at 
http://eldd.emcdda.eu.int/databases/eldd_comparative_analyses.cfm (accessed April 12 
2005) 
[31]   W. Thormann, I.S. Lurie, B. McCord, U. Marti, B. Cenni, N. Malik, Advances of capillary 
electrophoresis in clinical and forensic analysis (1999-2000). Electrophoresis, 22 (2001) 
4216–4243. 
[32]   SYDRUG: Interpol's global project on synthetic drugs. International Criminal Police 
Organization, Interpol, April, 2003, Lyon, France, p. 1–19. 
[33]   A. Allen, T.S. Cantrell, Synthetic reductions in clandestine amphetamine and 
methamphetamine laboratories: A review. Forensic Sci. Int., 42 (1989) 183–199. 
[34]   Development of a harmonised method for the profiling of amphetamines, final report. EU 
Project SMT-CT98-2277, June, 2003, National Bureau of Investigation, Finland. 
[35]   In: Martindale, The Complete Drug Reference, K. Parfitt, Ed., 32nd ed., Pharmaceutical 
Press, London, UK, e.g. p. 29 and 1063. 
[36]   I.S. Lurie, R.F.X. Klein, T.A. Dal Cason, M.J. LeBelle, R. Brenneisen, R.E. Weinberger, 
Chiral resolution of cationic drugs of forensic interest by capillary electrophoresis with 
mixtures of neutral and anionic cyclodextrins. Anal. Chem., 66 (1994) 4019–4026. 
[37]   J.K. Fallon, A.T. Kicman, J.A. Henry, P.J. Milligan, D.A. Cowan, A.J. Hutt. Stereospecific 
analysis and enantiomeric disposition of 3,4-MDMA (ecstasy) in humans. Clin. Chem., 45 
(1999) 1058–1069. 
[38]   D. de Boer, L.P. Tan, P. Gorter, R.M.A. van de Wal, J.J. Kettenes-van de Bosch, E.A. de 
Bruijn, R.A.A. Maes, GC/MS assay for profiling the enantiomers of 3,4-MDMA and its 
chiral metabolites using PICI-ion trap-MS. J. Mass Spectrom., 32 (1997) 1236–1246. 
  58 
[39]   M.D. Pastor-Navarro, R. Porras-Serrano, R. Herráez-Hernández, P. Falco, Automated 
determination of amphetamine enantiomers using two-dimensional column-switching 
chromatography system for derivatisation and separation. Analyst, 1998, 123, 319–324. 
[40]   R. Herráez-Hernández, P. Campins-Falco, L.A. Tortajada-Genaro, Chiral determination of 
amphetamine and related compounds using chloroformates for derivatization and LC. 
Analyst, 123 (1998) 2131–2137. 
[41]   R. Herráez-Hernández, P. Campins-Falco, J. Verdu-Andres, Enantiomeric separation of 
amphetamine and related compounds by LC using precolumn derivatization with o-
phtaldialdehyde. Chromatographia, 56 (2002) 559–565. 
[42]   D.W. Armstrong, K.L. Rundlett, U.B. Nair, G.L. Reid III, Enantioresolution of 
amphetamine, methamphetamine, and deprenyl (selegiline) by LC, GC, and CE. Current 
Sep., 15 (1996) 57–61. 
[43]   S.R. Wallenborg, I.S. Lurie, D.W. Arnold, C.G. Bailey, On-chip chiral and achiral 
separation of amphetamine and related compounds labeled with 4-fluoro-7-
nitrobenzofurane. Electrophoresis, 21 (2000) 3257–3263. 
[44]   M. Ludwig, F. Kohler, D. Belder, High-speed chiral separations on a microchip with UV 
detection. Electrophoresis, 24 (2003) 3233–3238. 
[45]   C. Slijkhuis, K.D. Hartog, C. van Alpen, L. Blok-Tip, P.M.J.M. Jongen, D. de Kaste, 
Analysis of optically active compounds using conventional chromatography with circular 
dicroism detector. J. Pharm. Biomed. Anal., 32 (2003) 905–912. 
[46]   Y. Makino, S. Ohta, M. Hirobe M. Enantiomeric separation of amphetamine by LC using 
chiral crown ether-coated RP packing: application to forensic analysis. Forensic Sci. Int., 
1996, 787, 65–70. 
[47]   M. Brunnenberg, K.-A. Kovar, Stereospecific analysis of ecstasy-like MDEA and its 
metabolites in human. J. Chromatogr. B, 751 (2001) 9–18. 
[48]   K. Matsushima, T. Nagai, H. Nihei, F. Kikuchi, S. Tokudome, Case report - Analysis of a 
new type tablet containing l(-)–methamphetamine. Jap. J. Sci. Technol. Ident., 8 (2003) 99–
102. 
[49]   J. Buechler, M. Schwab, G. Mikus, B. Fischer, L. Hermle, C. Marx, G. Grön, M. Spitzer, 
K.A. Kovar, Enantioselective quantitation of the ecstasy compounds (R)- and (S)-N-ethyl-
3,4-methylenedioxyamphetamine and its major metabolites in human plasma and urine. J. 
Chromatogr. B, 793 (2003) 207–222. 
[50]   A.C. Lua, T.-Y. Chou, Preparation of immunoaffinity columns for direct enantiomeric 
separation of amphetamine and/or methamphetamine. J. Chromatogr. A, 967 (2002) 191–
199. 
[51]   M. P. Gasper, A. Berthod, U.B. Nair, D.W. Armstrong. Comparison and modelling study of 
vancomysin, ristocetin A, and teicoplanin for CE enantioseparation. J. Chromatogr. A, 68 
(1996) 2501–2514. 
[52]   T.J Ward, A.B. Farris III, Chiral separations using the macrocyclic antibiotics: a review. J. 
Chromatogr. A, 906 (2001) 73–89.  
[53]   Chirobiotic handbook, 4th ed., Advanced Separation Technologies, 2002. 
[54]   D.W. Armstrong, Y. Tang, S. Chen, Y. Zhou, C. Bagwill, J.-R. Chen, Macrocyclic 
antibiotics as a new class of chiral selectors for LC. Anal. Chem., 66 (1994) 1473–1484. 
[55]   D.W. Armstrong, Y.W. Zhou. Use of macrocyclic antibiotic as a chiral selector for the 
enantiomeric separation by TLC. J. Liq. Chromatogr., 17 (1994) 1695–1707. 
[56]  Q. Sun, S.V. Olesik. Chiral separations performed by enhanced-fluidity LC on a 
macrocyclic antibiotic CSP. Anal. Chem., 71 (1999) 2139–2145.  
[57]   J. Dönnecke, L.A. Svensson, O. Gyllenhaal, K.-E. Karlsson, A. Karlsson, J. Vessman, 
Evaluation of a vancomysin chiral stationary phase in packed capillary supercritical fluid 
chromatography. J. Microcol. Sep., 11 (1999) 521–533. 
[58]   H. Wikström, L.A. Svensson, A. Torstensson, P.K. Owens. Immobilisation and evaluation 
of a vancomysin chiral stationary phase for capillary electrochromatography. J. Chromatogr. 
A, 869 (2000) 395– 409.  
  59
[59]   S. Fanali, C. Desiderio, G. Schulte, S. Heitmeier, D. Strickmann, B. Chankvedatze, G. 
Blasche, Chiral capillary electrophoresis-electrospray mass spectrometry coupling using 
vancomysin as a chiral selector. J. Chromatogr. A, 800 (1998) 69–76. 
[60]   L. Ramos, R. Bakhtiar, T. Majumbar, M. Hayes, F. Tse. LC–APCI/MS/MS enantiomeric 
separation of dl-threo-methylphenidate (Ritalin) using macrocyclic antibiotic as the chiral 
selector. Rapid Comm. Mass Spectrom., 13 (1999) 2054–2062. 
[61]   R. Bakhtiar, F.L.S. Tse, High-throughput chiral LC–MS/MS. Rapid Comm. Mass 
Spectrom., 14 (2000) 1128–1135. 
[62]   E. Tesarová, K. Záruba, M. Flieger, Enantionseparation of semisynthetic ergot alkaloids on 
vancomysin and teicoplanin stationary phases. J. Chromatogr. A, 844 (1999) 137–147. 
[63]   M. Katagi, H. Nishioka, K. Nakajima, H. Tsuchihashi, Analysis of the enantiomers of 
methamphetamine and amphetamine in urine by LC and LC–MS. (Hochudoku) Jap. J. 
Forensic. Toxicol., 12 (1994) 158–159. 
[64]   M. Katagi, M. Nishikawa, M. Tatsuno, T. Miyazawa, H. Tsuchihashi, A. Suzuki, O. Shirota, 
Direct analysis of methamphetamine and amphetamine enantiomers in human urine by 
semi-microcolumn LC–ESI/MS. Jap. J. Toxicol. Env. Health, 44 (1998) 107–115. 
[65]   M.J. LeBelle, C. Savard, B.A. Dawson, D.B. Black, L.K. Katyal, F. Zrcek, A.W. By, Chiral 
identification and determination of ephedrine, pseudoephedrine, methamphetamine and 
methcatinone by GC and NMR. Forensic Sci. Int., 71 (1995) 215–223. 
[66]   D. Hensley, J. T. Cody, Simultaneous determination of amphetamine, methamphetamine, 
methylenedioxyamphetamine (MDA), methylenedioxymethamphetamine (MDMA), and 
methylenedioxyethylamphetamine (MDEA) enantiomers by GC–MS. J. Anal. Toxicol., 23 
(1999) 518–523. 
[67]   N. Pizarro, A. Llebaria, S. Cano, J. Joglar, M. Farre, J. Segura, R. de la Torre, 
Stereochemical analysis of 3,4-MDMA and its main metabolites by GC–MS. Rapid Comm. 
Mass Spectrom., 17 (2003) 330–336. 
[68]   I.S. Lurie, Micellar electrokinetic capillary chromatography of the enantiomers of 
amphetamine, methamphetamine and their hydroxyphenethylamine precursors. J. 
Chromatogr., 605 (1992) 269–275. 
[69]   A. Aumatell, R.J. Wells, D.K.Y. Wong, Enantiomeric differentiation of a wide range of 
pharmacologically active substances by CE using modified cyclodextrins. J. Chromatogr. A, 
686 (1994) 293–307. 
[70]   C.L. Flurer, L.A. Lin, D. Satzger, K.A. Wolnik, Determination of ephedrine compounds in 
nutritional supplements by CD-modified CE. J. Chromatogr. B, 669 (1995) 133–139. 
[71]   S. Cladrowa-Runge, R. Hirz, E. Kenndler, A. Rizzi, Enantiomeric separation of 
amphetamine related drugs by capillary zone electrophoresis using native and derivatized β-
CD as chiral additives. J. Chromatogr. A, 710 (1995) 339–345. 
[72]   E. Varesio, J.-L. Veuthey, Chiral separation of amphetamines by HPCE. J. Chromatogr. A, 
717 (1995) 219–228. 
[73]   H.-J. Gaus, Z.Z. Gogus, K. Schmeer, B. Behnke, K.-A. Kovar, E. Bayer, Separation and 
identification of designer drugs with CE and on-line connection with ion spray/MS. J. 
Chromatogr. A, 735 (1996) 221–226. 
[74]   Z. Wang, Y. Sun, Z. Sun, Enantiomeric separation of amphetamine and phenylephrine by 
cyclodextrin-mediated capillary zone electrophoresis. J. Chromatogr. A, 735 (1996) 295–
301. 
[75]   T. Scarcella, F. Tagliaro, S. Turrina, G. Manetto, Y. Nakahara, F.P. Smith, M. Marigo, 
Optimisation of a simple method for the chiral separation of phenethylamines of forensic 
interest based on cyclodextrin complexation capillary electrophoresis and its preliminary 
application to the analysis of human urine and hair. Forensic Sci. Int., 89 (1997) 33–46. 
[76]   S. Chinaka, S. Tanaka, N. Takayama, K. Komai, T. Ohshima, K. Ueda, Simultaneous chiral 
analysis of methamphetamine and related compounds by capillary electrophoresis. J. 
Chromatogr. B, 749 (2000) 111–118. 
  60 
[77]   N. Ye, X. Gu, H. Zou, R. Zhu, Separation and determination of ephedrine enantiomers by 
capillary electrophoresis using l-leucine as chiral selector. Chromatographia, 56 (2002) 637–
639. 
[78]   Y.T. Iwata, A. Garcia, T. Kanamori, H. Inoue, T. Kishi, I.S. Lurie, The use of highly 
sulphated cyclodextrin for the simultaneous chiral separation of amphetamine-type 
stimulants by capillary electrophoresis. Electrophoresis, 23 (2002) 1328–1334. 
[79]   W.-C. Cheng, W.-M. Lee, M.-F. Chan, P. Tsui, K.-L. Dao, Enantiomeric separation of 
methamphetamine and related analogs by capillary zone electrophoresis: Intelligence study 
in routine methamphetamine seizures. J. Forensic Sci., 47 (2002) 1248–1252. 
[80]   A.-S. Liau, J.-T. Liu, L.-C. Lin, Y.-C. Chiu, Y.-R. Shu, C.-C. Tsai, C.-H. Lin, Optimization 
of a simple method for the chiral separation of methamphetamine and related compounds in 
clandestine tablets and urine samples by β-CD modified capillary electrophoresis: a 
complementary method to GC–MS. Forensic Sci. Int., 134 (2003) 14–24. 
[81]   Y. T. Iwata, T. Kanamori, Y. Ohmae, K. Tsujikawa, H. Inoue, T. Kishi, Chiral analysis of 
amphetamine-type stimulants using reversed-polarity capillary electrophoresis–positive ion 
electrospray ionization tandem mass spectrometry. Electrophoresis, 24 (2003) 1770–1776. 
[82]   F.T. Noggle Jr., J. DeRuiter, C.R. Clark, Liquid chromatographic determination of the 
enantiomeric composition of methamphetamine prepared from ephedrine and 
pseudoephedrine. Anal. Chem., 58 (1986) 1643–1648. 
[83]   S.M. Hayes, R.H. Liu, W.-S. Tsang, M. G. Legendre, R.J. Berni, D.J. Pillion, S. Barnes, 
M.H. Ho, Enantiomeric composition analysis of amphetamine and methamphetamine by 
chiral phase LC–MS. J. Chromatogr., 398 (1987) 239–246. 
[84]   A.M. Rizzi, R. Hirz, S. Cladrowa-Runge, H. Jonsson, Enantiomeric separation of 
amphetamine, methamphetamine and ring substituted amphetamines by means of a β-CD 
chiral stationary phase. Chromatographia, 39 (1994) 131–137. 
[85]   K. Lemr, D. Jirovský, J. Ševèík, Effect of some parameters on enantiomer separation of 
ephedrine, methamphetamine, and selegiline using LC with β-CD chiral stationary phase. J. 
Liq. Chrom. & Rel. Technol., 19 (1996) 3173–3191. 
[86]   M. Katagi, H. Nishioka, K. Nakajima, H. Tsuchihashi, H. Fujima, H. Wada, K. Nakamura, 
K. Makino, Direct LC and LC–TSP/MS determination of enantiomers of methamphetamine 
and its main metabolites amphetamine and p-hydroxymethamphetamine in human urine. J. 
Chromatogr. B, 676 (1996) 35–43. 
[87]   F. Sadeghipour, J.L. Veuthey, Enantiomeric separation of four methylenedioxylated 
amphetamines on β-CD chiral stationary phases. Chromatographia, 47 (1998) 285–290. 
[88]   S. Brombacher, S.J. Owen, D.A. Volmer, Automated coupling of capillary-LC to matrix-
assisted laser desorption/ionization mass spectrometry for the analysis of small molecules 
utilizing reactive matrix. Anal. Bioanal. Chem., 376 (2003) 773–779. 
[89]   E. Nägele, M. Vollmer, Coupling of nanoflow LC to matrix-assisted laser 
desorption/ionization mass spectrometry: real-time LC run mapping on a MALDI plate. 
Rapid Comm. Mass Spectrom., 18 (2004) 3008–3014. 
[90]   M.J. Bogusz, K.-D. Krüger, R.-D. Maier, Analysis of underivatised amphetamines and 
related phenethylamines with LC–APCI/MS. J. Anal. Toxicol., 24 (2000) 77–84. 
[91]   K.A. Mortier, R. Dams, W.E. Lambert, E.A. De Letter, S. Van Calenbergh, A.P. De 
Leenheer, Determination of paramethoxyamphetamine and other amphetamine-related 
designer drugs by LC–sonic spray ionization/MS. Rapid. Commun. Mass Spectrom., 16 
(2002) 865–870. 
[92]   D. Hasman, Presentation abstract, Abstracts from the 50th annual meeting in Vancouver, 
March 25 – 29, 2003. J. Can. Soc. Forensic Sci., 36 (2003) 49–71. 
[93]   Liquid chromatography–mass spectrometry, W.M.A. Niessen, ed., 2nd ed., Chromatographic 
science series, Vol. 79, Marcel Dekker, New York, 1999, p. 260–283. 
[94]   P. Kebarle, Y. Ho in: Electrospray ionization mass spectrometry: fundamentals, 
instrumentation, and applications, R.B. Cole, ed., Wiley Interscience, New York, 1997. p. 3 
–63. 
  61
[95]   P. Kebarle, A brief overview of the present status of the mechanisms involved in 
electrospray mass spectrometry. J. Mass Spectrom., 35 (2000) 804–817. 
[96]   M. Karas, F. Hillenkamp, Laser desorption ionization of proteins with molecular masses 
exceeding 10000 Daltons. Anal. Chem., 60 (1988) 2299–2301. 
[97]   F. Hillenkamp, M. Karas, R.C. Beavis, B.T. Chait, Matrix-assisted laser 
desorption/ionization mass spectrometry of biopolymers. Anal. Chem., 63 (1991) 1193A–
1203A. 
[98]   G. Siuzdak, The expanding role of mass spectrometry in biotechnology, 1st ed., MCC Press, 
San Diego, USA, 2003, p. 23–29. 
[99]   V.V. Laiko, M.A. Baldwin, A.L. Burlingame, Atmospheric pressure matrix-assisted laser 
desorption/ionization mass spectrometry. Anal. Chem., 72 (2000) 652–657. 
[100]   S.C. Moyer, R.J. Cotter, Atmospheric pressure MALDI. Anal. Chem., 74 (2002) 469A–
476A. 
[101]   V.V. Laiko, N.I. Taranenko, V.D. Berkout, B.D. Musselman, V.M. Doroshenko, 
Atmospheric pressure laser desorption/ionization on porous silicon. Rapid Commun Mass 
Spectrom., 16 (2002) 1737–1742. 
[102]   J. Wei, M. Jillian, G. Siuzdak, Desorption-ionization mass spectrometry on porous silicon. 
Nature, 399 (1999) 243–246. 
[103]   J.J. Thomas, Z. Shen, J.E. Crowell, M.G. Finn, G. Siuzdak, Desorption/ionization on silicon 
(DIOS): a diverse mass spectrometry platform for protein characterization. PNAS, 98 
(2001) 4932–4937. 
[104]   Z. Shen, J.J. Thomas, C. Averbuj, M. Klas, M. Engelhard, J.E. Crowell, M.G. Finn, G. 
Siuzdak, Porous silicon as a versatile platform for laser desorption/ionization mass 
spectrometry. Anal. Chem., 73 (2001) 612–619. 
[105]   R.A. Kruse, X. Li, P.W. Bohn, J.V. Sweedler, Experimental factors controlling analyte ion 
generation in laser desorption/ionization mass spectrometry on porous silicon. Anal. Chem., 
73 (2001) 3639–3645. 
[106]   S. Tuomikoski, K. Huikko, K. Grigoras, P. Östman, R. Kostiainen, M. Baumann, J. Abian, 
T. Kotiaho, S. Franssila, Preparation of porous n-type silicon samples for 
desorption/ionization on silicon MS (DIOS–MS). Lab on a Chip, 2 (2002) 247–253. 
[107]   T.N. Decaestecker, K.M. Clauwaert, J.F. Van Bocxlaer, W.E. Lambert, E.G. Van den 
Eeckhout, C.H. Van Peteghem, A.P. De Leenheer, Evaluation of automated single MS to 
tandem MS function switching for comprehensive drug profiling analysis using a 
quadrupole TOF MS. Rapid Commun. Mass Spectrom., 14 (2000) 1787–1792. 
[108]   W. Weinmann, M. Svoboda, Fast screening for drugs of abuse by SPE combined with flow-
injection–ionspray/MS. J. Anal. Toxicol., 22 (1998) 319–328. 
[109]   D.S. Selby, M. Guilhaus, J. Murby, R.J. Wells, Direct quantification of alkaloid mixtures by 
electrospray ionization mass spectrometry. J. Mass Spectrom., 33 (1998) 1232–1236. 
[110]   P. Kebarle, L. Tang, From ions in solution to ions in the gas phase. The mechanism of 
electrospray mass spectrometry. Anal. Chem., 65 (1993) 972A–999A. 
[111]   I.M. Lazar, G. Naisbitt, M.L. Lee, Capillary electrophoresis–time-of-flight mass 
spectrometry of drugs of abuse. Analyst, 123 (1998) 1449–1454. 
[112]   I.M. Lazar, G. Naisbitt, M.L. Lee, Capillary electrophoresis–time-of-flight mass 
spectrometry of an opium powder. Chromatographia, 50 (1999) 188–194. 
[113]   A. Ramseier, C. Siethoff, J. Caslavska, W. Thormann, Confirmation testing of 
amphetamines and designer drugs in human urine by capillary electrophoresis–ion trap MS. 
Electrophoresis, 21 (2000) 380–387. 
[114]   A.B. Wey, W. Thormann, Head-column field-amplified sample stacking in presence of 
siphoning. Application to CE–ESI/MS of opioids in urine. J. Chromatogr. A, 924 (2001) 
507–518. 
[115]   G. Boatto, M. Nieddu, A. Carta, A. Pau, M. Palomba, B. Asproni, R. Cerri, Determination 
of amphetamine-derived designer drugs in human urine by solid phase extraction and CE 
with MS detection. J. Chromatogr. B, 814 (2005) 93–98. 
  62 
[116]   P. Hatsis, S. Brombacher, J. Corr, P. Kovarik, D.A. Volmer, Quantitative analysis of small 
pharmaceutical drugs using a high repetition laser matrix-assisted laser/desorption 
ionization source. Rapid Comm. Mass Spectrom., 17 (2003) 2303–2309. 
[117]   A. Kraj, T. Dylag, A. Gorecka-Drzazga, S. Bargiel,  J. Dziubanand, J. Silberring, 
Desorption/ionization on silicon for small molecules: a promising alternative to MALDI 
TOF. Acta Biochim. Pol., 50 (2003) 783–787. 
[118]   T.P.E. Hollenbeck, G. Siuzdak, R.D. Blackledge, Electrospray and MALDI mass 
spectrometry in the identification of spermicides in criminal investigations. J. Forensic Sci., 
44 (1999) 783–788. 
[119]   J.J. Thomas, Z. Shen, R. Blackledge, G. Siuzdak, Desorption-ionization on silicon mass 
spectrometry: an application in forensics. Anal. Chim. Acta, 442 (2001) 183–190. 
[120]   Z. Shen, J.J. Thomas, G. Siuzdak, R.D. Blackledge, A case study on forensic polymer 
analysis by DIOS-MS: the suspect who gave us the SLIP. J Forensic Sci., 49 (2004) 1028–
1035. 
[121]   W.E. Steiner, B.H. Clowers, W.A. English, H.H. Hill Jr, Atmospheric pressure matrix-
assisted laser desorption/ionization with analysis by ion mobility time-of-flight mass 
spectrometry. Rapid Commun Mass Spectrom., 18 (2004) 882–888. 
[122]   K. Huikko, P. Östman, C. Sauber, F. Mandel, K. Grigoras, S. Franssila, T. Kotiaho, R. 
Kostiainen, Feasibility of atmospheric pressure desorption/ionization on silicon mass 
spectrometry in analysis of drugs. Rapid Comm. Mass Spectrom., 17 (2003) 1339–1343. 
[123]   E.P. Go, J.E. Prenni, J. Wei, A. Jones, S.C. Hall, H.E. Witkowska, Z. Shen, G. Siuzdak, 
Desorption/ionization on silicon time-of-flight/time-of-light mass spectrometry. Anal. 
Chem., 75 (2003) 2504–2506. 
[124]   H. Hoja, P. Marquet, B. Verneuil, H. Lotfi, B. Pénicaut, G. Lachâtre, Applications of LC–
MS in analytical toxicology: A review. J. Anal. Toxicol., 21 (1997) 116–126. 
[125]   H.H. Maurer, LC–MS in forensic and clinical toxicology, review. J. Chromatogr. B, 713 
(1998) 3–25. 
[126]   P. Marquet, G. Lachâtre, LC–MS: potential in forensic and clinical toxicology. J. 
Chromatogr. B, 733 (1999) 93–118. 
[127]   M.J. Bogusz, LC–MS as a routine method in forensic sciences: proof of maturity. J. 
Chromatogr. B, 748 (2000) 3–19. 
[128]   C.-K. Lim, G. Lord, Current developments in LC–MS for pharmaceutical analysis. A 
review. Biol. Pharm. Bull., 25 (2002)547–557. 
[129]   K. Kudo, H. Tsuchihashi, N. Ikeda, Meeting challenges in forensic toxicology in Japan by 
LC–MS. A review. Anal. Chim. Acta, 492 (2003) 83–104.  
[130]   P. Marquet, Progress of LC–MS in clinical and forensic toxicology. Ther. Drug Monit., 24 
(2002) 255–276. 
[131]   R.F.X. Klein, P.A. Haynes, Detection and analysis of drugs of forensic interest, 1992 – 
2001; A literature review. Microgram Journal, 1 (2003) 55–153. (1377 references) 
[132]   R.F.X. Klein, P.A. Hays, Research on drug evidence. Proceeding, 13th INTERPOL Forensic 
Science Symposium, Lyon, France, 2001, D3-1–D3-51. (406 references) 
[133]   P.M Jeanville, E.S. Estapé, I. Torres-Negrón, A. Martí, Rapid confirmation/quantitation of 
ecgonine methyl ester, benzoylecgonine, and cocaine in urine using on-line extraction 
coupled with fast LC and tandem mass spectrometry. J. Anal. Toxicol., 25 (2001) 69–75. 
[134]   N. Wu, D.C. Collins, J.A. Lippert, Y. Xiang, M.L. Lee, Ultrahigh pressure liquid 
chromatography–time-of-flight mass spectrometry for fast separations. J. Microcolumn 
Sep., 12 (2000) 462–469. 
[135]   S. Laks, A. Pelander, E. Vuori, E. Ali-Tolppa, E. Sippola, I Ojanperä, Analysis of street 
drugs in seized material without primary reference standards. Anal. Chem., 76 (2004) 7375–
7379. 
[136]   K.M Clauwaert, J.F. Van Bocxlaer, H.J. Major, J.A. Claereboudt, W.E. Lambert, E.M. Van 
den Eeckhout, C.H. Van Peteghem, A.P. De Leenheer, Investigation of the quantitative 
properties of the quadrupole orthogonal acceleration time-of-flight mass spectrometer with 
  63
electrospray ionisation using 3,4-methylenedioxymethamphetamine. Rapid Comm. Mass 
Spectrom., 13 (1999) 1540–1545. 
[137]   M.J. Bogusz, R.-D. Maier, A. Th. Schäfer, M. Erkens, Honey with Psilocybe mushrooms: a 
revival as very old preparation on the drug market? Int. J. Legal Med., 111 (1998) 147–150. 
[138]   K. Saito, T. Toyo’oka, T. Fukushima, M. Kato, O. Shirota, Y. Goda, Determination of 
psilocin in magic mushrooms and rat plasma by LC with fluorimetry and ESI/MS. Anal. 
Chim. Acta, 527 (2004) 149–156. 
[139]   S. McClean, E. O'Kane, J. Hillis, W.F. Smyth, Determination of 1,4-benzodiazepines and 
their metabolites by capillary electrophoresis and LC using UV and ESI/MS. J. Chromatogr. 
A, 838 (1999) 273–291. 
[140]   H. Yuan, Z. Mester, H. Lord, J. Pawliszyn, Automated in-tube solid-phase microextraction 
coupled with LC–ESI/MS for the determination of selected benzodiazepines. J. Anal. 
Toxicol., 24 (2000) 718–725. 
[141]   Z. Liu, J. Short, A. Rose, S. Ren, N. Contel, S. Grossman, S. Unger, The simultaneous 
determination of diazepam and its three metabolites in dog plasma by LC–MS. J. Pharm. 
Biomed. Anal., 26 (2001) 321–330. 
[142]   A. Miki, M. Tatsunom M. Katagi, M. Nishikawa, H. Tsuchihashi, Simultaneous 
determination of eleven benzodiazepine hypnotics and eleven relevant metabolites in urine 
by column-switching LC–MS. J. Anal. Toxicol., 26 (2002) 87–93. 
[143]   M. Wood, G. De Boeck, N. Samyn, V. Maes, M. Morris, Development of a rapid and 
sensitive method for the quantification of benzodiazepines in human plasma by LC–
MS/MS. Poster reprint, TIAFT, Paris, 2002. 
[144]   F.E. Dussy, C. Hamberg Stäubli, T.A. Briellmann, The application of LC–MS in forensic 
toxicology. Chimia, 56 (2002) 53–58. 
[145]   H. Zeng, Y. Deng, J.-T. Wu, Fast analysis using monolithic columns coupled with high-flow 
on-line extraction and electrospray mass spectrometric detection for the direct and 
simultaneous quantitation of multiple components in plasma. J. Chromatogr. B, 788 (2003) 
331–337. 
[146]   B.E. Smink, J.E. Brandsma, A. Dijkhuizen, K.J. Lusthof, J.J. de Gier, A.C.G. Egberts, 
D.R.A. Uges. Quantitative analysis of 33 benzodiazepine-like substances in whole blood by 
LC–(tandem) MS. J. Chromatogr. B, 811 (2004) 13–20.  
[147]   C. Kratzsch, O. Tenberken, F.T. Peters, A.A. Weber, T. Kraemer, H.H. Maurer, Screening, 
library-assisted identification and validated quantification of 23 benzodiazepines, 
flumazenil, zaleplone, zolpidem and zopiclone in plasma by LC–MS with atmospheric 
pressure chemical ionization. J. Mass Spectrom., 39 (2004) 856–872. 
[148]   M. Walles, W.M. Mullett, J. Pawliszyn, Monitoring of drugs and metabolites in whole blood 
by restricted-access solid-phase microextraction coupled to LC–MS. J. Chromatogr. A, 1025 
(2004) 85–92. 
[149]   M. Katagi, M. Tatsuno, A. Miki, M. Nishikawa, H. Tsuchihashi, Discrimination of 
dimethylamphetamine and methamphetamine use: simultaneous determination of 
dimethylamphetamine-N-oxide and other metabolites in urine by LC–ESI/MS. J. Anal. 
Toxicol., 24 (2000) 354–358. 
[150]   M.J. Bogusz, K.-D. Krueger, R.-D. Maier, Analysis of underivatised amphetamines and 
related phenetylamines with LC–APCI/MS. J. Anal. Toxicol., 24 (2000) 77–84. 
[151]   C.R. Borges, D.G. Wilkins, D.E. Rollins, Amphetamine and N-acetylamphetamine 
incorporation into hair: an investigation of potential role of drug basicity in hair color bias. 
J. Anal. Toxicol., 25 (2001) 221–227. 
[152]   M. Wood, G. DeBoeck, N. Samyn, D. Cooper, M. Morris, Rave on!: Quantification of 
amphetamines in plasma. Micromass Application Brief AB 46, November 2001, Version 1. 
[153]   M. Wood, G. De Boeck, N. Samyn, D. Cooper, M. Morris, Development of a rapid and 
sensitive method for the quantitation of amphetamines in human saliva. Presented at SOFT, 
New Orleans, 2001. 
[154]   K.A. Mortier, K.E., Maudens, W.E. Lambert, K.M. Clauwaert, J.F. Van Bocxlaer, D.L. 
Deforece, C.H. Van Peteghem, A.P. De Leenheer, Simultaneous, quantitative determination 
  64 
of opiates, amphetamines, cocaine and benzoylecgonine in oral fluid by LC–QTOF-MS. J. 
Chromatogr. B, 779 (2002) 321–330. 
[155]   M. Sato, M. Hida, H. Nagase, Analysis of dimethylamphetamine and its metabolites in 
human urine by LC–ESI/MS with direct sample injection. Forensic Sci. Int., 128 (2002) 
146–154. 
[156]   M. Wood, G. De Boeck, N. Samyn, M. Morris, D.P Cooper, R.A.A. Maes, E.A. De Bruijn, 
Development of a rapid and sensitive method for the quantitation of amphetamines in 
human plasma and oral fluid by LC–MS/MS. J. Anal. Toxicol., 27 (2003) 78–87. 
[157]   D.N. Heller, LC/MS for timely response in regulatory analyses: identification of 
pentobarbital in dog food. Anal. Chem., 72 (2000) 2711–2716. 
[158]   S.R. Needham, P.M. Jeanville, P.R. Brown, E.S. Estape, Performance of a 
pentafluorophenylpropyl stationary phase for the electrospray ionization LC–MS/MS assay 
of cocaine and its metabolite ecgonine methyl ester in human urine. J.Chromatogr. B, 748 
(2000) 77–87. 
[159]   Y. Xia, P. Wang, M.G. Bartlett, H.M. Solomon, K.L. Busch, An LC–MS/MS method for the 
comprehensive analysis of cocaine and cocaine metabolites in meconium. Anal. Chem., 72 
(2000) 764–771. 
[160]   K. Srinivasan, P. Wang, A.T Eley, C.A. White, M.G. Bartlett, LC–MS/MS analysis of 
cocaine and its metabolites from blood, amniotic fluid, placental and fetal tissues: study of 
the metabolism and distribution of cocaine in pregnant rats. J. Chromatogr. B, 745 (2000) 
287–303. 
[161]   M.-R. Fuh, Y.-L. Tai, W.H.T. Pan, Determination of free-form of cocaine in rat brain by 
LC–ESI/MS with in vivo microdialysis. J.Chromatogr. B, 752 (2001) 107–114. 
[162]   R.B. Paulsen, D.G. Wilkins, M.H. Slawson, K. Shaw, D.E. Rollins, Effect of four laboratory 
decontamination procedures on the quantitative determination of cocaine and metabolites in 
hair by LC–MS. J. Anal. Toxicol., 25 (2001) 490–496. 
[163]   S.-N. Lin, D.E Moody, G. Bigelow, R.L. Foltz, A validated LC–APCI/MS/MS method for 
quantitation of cocaine and benzoylecgonine in human plasma. J. Anal. Toxicol., 25 (2001) 
497–503. 
[164]   Klingmann A, Skopp G, Aderjan R, Analysis of cocaine, benzoylecgonine, ecgonine methyl 
ester, and ecgonine by LC–API/MS and application to a short-term degradation study of 
cocaine in plasma. J. Anal. Toxicol., 25 (2001) 425–430. 
[165]   S.-N. Lin, S.L. Walsh, D.E. Moody, R.L. Foltz, Detection and time course of cocaine N-
oxide and other cocaine metabolites in human plasma by LC–MS/MS. Anal. Chem., 75 
(2003) 4335–4340. 
[166]   M.E.P. Hows, L. Lacroix, C. Heidbreder, A.J. Organ, A.J. Shah, LC–MS/MS assay for the 
simultaneous measurement of dopamine, norepinephrine, 5-hydroxytryptamine and cocaine 
in biological samples. J. Neurosci. Meth., 138 (2004) 123–132. 
[167]   S.A. Schlueter, J.D. Hutchison Jr., J.M. Hughes, Determination of opiates and metabolites in 
blood using electrospray LC/MS. Agilent Technologies, Application note, 5988-4805EN, 
December 1st, 2001. 
[168]   W.Z. Shou, M. Pelzer, T. Addison, X. Jiang, W. Naidong, An automatic 96-well solid-phase 
extraction and LC–MS/MS method for the analysis of morphine, morphine-3-glucuronide 
and morphine-6-glucuronide in human plasma. J. Pharm. Biomed. Anal., 27 (2002) 143–
152. 
[169]   R. Dams, C.M. Murphy, R.E. Choo, W.E. Lambert, A.P. De Leenheer, M.A. Huestis, LC–
APCI/MS/MS analysis of multiple illicit drugs, methadone, and their metabolites in oral 
fluid following protein precipitation. Anal. Chem., 75 (2003) 798–804. 
[170]   D. Whittington, E.D. Kharasch, Determination of morphine and morphine glucuronides in 
human plasma by 96-well plate solid-phase extraction and LC–ESI/MS. J. Chromatogr. B, 
796 (2003) 95–103. 
[171]   S. Pichini, R. Pacifici, M. Pellegrini, E. Marchei, E. Pérez-Alarcón, C. Puig, O. Vall, O. 
García-Algar, Development and validation of a LC–MS assay for the determination of 
opiates and cocaine in meconium. J. Chromatogr. B, 794 (2003) 281–292. 
  65
[172]   T.N. Decaestecker, W.E. Lambert, C.H. Van Peteghem, D. Deforce, J.F. Van Bocxlaer, 
Optimization of solid-phase extraction for a LC–MS/MS general unknown screening 
procedure by means of computational techniques. J. Chromatogr. A, 1056 (2004) 57–65. 
[173]    T.N. Decaestecker, S.R. Vande Casteele, P.E. Wallemacq, C.H. Van Peteghem, D.L. 
Defore, J.F. Van Bocxlaer, Information-dependant acquisition-mediated LC–MS/MS 
screening procedure with semiquantitative potential. Anal. Chem., 76 (2004) 6365–6373. 
[174]   M. Mabuchi, S. Takatsuka, M. Matsuoka, K. Tagawa, Determination of morphine, 
morphine-3-glucuronide and morphine-6-glucuronide in monkey and dog plasma by LC–
ESI/MS/MS. J. Pharm. Biomed. Anal., 35 (2004) 563–573. 
[175]    J.L.E. Reubsaet, S. Pedersen-Bjergaard, Screening for central nervous system-stimulating 
drugs in human plasma by LC with MS detection. J. Chromatogr. A, 1031 (2004) 203–211. 
[176]   B. Maralikova, W. Weinmann, Confirmatory analysis for drugs of abuse in plasma and 
urine by LC–MS/MS with respect to criteria for compound identification. J. Chromatogr. B, 
811 (2004) 21–30. 
[177]   K.B. Scheidweiler, M.A. Huestis, Simultaneous quantification of opiates, cocaine, and 
metabolites in hair by LC–APCI/MS/MS. Anal. Chem., 76 (2004) 4358–4363. 
[178]   J. Canezin, A. Cailleux, A. Turcant, A. Le Bouil, P. Harry, P. Allain, Determination of LSD 
and its metabolites in human biological fluids by LC with ESI/MS/MS. J. Chromatogr. B, 
165 (2001) 15–27. 
[179]   K. Bodin, J.-O. Svensson, Determination of LSD in urine with LC–MS. Ther. Drug. Monit., 
23 (2001) 389–393.  
[180]   A. Polettini, M.A. Huestis, Simultaneous determination of buprenorphine, 
norbuprenorphine, and buprenorphine-glucuronide in plasma by LC–MS/MS. J. 
Chromatogr. B, 754 (2001) 447–459. 
[181]   A. Ceccato, R. Klinkenberg, Ph. Hubert, B. Streel, Sensitive determination of buprenorphine 
and its N-dealkylated metabolite norbuprenorphine in human plasma by LC coupled to 
tandem mass spectrometry. J. Pharm. Biomed. Anal., 32 (2003) 619–631. 
[182]   L.A. Aalberg, Chromatographic and mass spectral studies on regioisomeric and mass 
equivalent derivatives related to the methylenedioxyphenethylamines. Acad. Diss., Auburn 
Univ., Auburn, AL, USA, 2002, p. 110–125 (literature review on synthesis) and p. 200–225 
(synthesis methods). 
[183]   R. Kostiainen, A.P. Bruins, Effect of multiple sprayers on dynamic range and flow rate 
limitations in electrospray and ionspray mass spectrometry. Rapid Comm. Mass Spectrom., 
8 (1994) 549–558. 
[184]   F. W. McLafferty, F. Turecek, Interpretation of Mass Spectra, 4th edition, University 
Science Books, Sausalito, California, 1993, xvii. 
[185]   V.M. Doroshenko, V.V. Laiko, N.I. Taranenko, V.D. Berkout, H.S. Lee. Recent 
developments in atmospheric pressure MALDI mass spectrometry. Int. J. Mass Spectrom., 
221 (2002) 39–58. 
[186]  R. Arakawa, Y. Shimomae, H. Morikawa, K. Ohara, S. Okuno, Mass spectrometric analysis 
of low molecular mass polyesters by laser desorption/ionization on porous silicon. J. Mass 
Spectrom., 39 (2004) 961–965. 
[187]  List of precursors and chemicals frequently used in the illicit manufacture of narcotic drugs 
and psychotropic substances under international control. 8th Edition, January 2004. Red list 
at: http://www.incb.org/e/ind_list.htm (Accessed February 7 2005) 
[188]  Chirobiotic Handbook, 5th ed., Astec, Whippany, 2004 (http://www.astecusa.com, accessed 
April 12 2005) 
[189]  K.H. Ekborg-Ott, Y. Liu, D.W. Armstrong. Highly enantioselective LC separations using 
the covalently bonded macrocyclic antibiotic, Ristocetin A, chiral stationary phase. 
Chirality, 10 (1998) 434–483. 
 
